

CALIFORNIA ENVIRONMENTAL CONTAMINANT  
BIOMONITORING PROGRAM  
(BIOMONITORING CALIFORNIA)  
SCIENTIFIC GUIDANCE PANEL MEETING  
CONVENED VIA HYBRID FORMAT BY:  
OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT  
CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY  
STATE OF CALIFORNIA

ELIHU M. HARRIS STATE OFFICE BUILDING  
GEORGE ALEXEEFF ENVIRONMENTAL HEALTH LIBRARY  
16TH FLOOR  
1515 CLAY STREET  
OAKLAND, CALIFORNIA

FRIDAY, NOVEMBER 14, 2025  
1:00 P.M.

JAMES F. PETERS, CSR  
CERTIFIED SHORTHAND REPORTER  
LICENSE NUMBER 10063

J&K COURT REPORTING, LLC

## APPEARANCES

### PANEL MEMBERS:

Amy Padula, PhD, MSc, Acting Chair

Carl F. Cranor, PhD, MSL

Lara Cushing, PhD, MPH(Remote)

Timur S. Durrani, MD, MPH, MBA

Oliver Fiehn, PhD

Ulrike Luderer, MD, PhD(Remote)

Thomas McKone, PhD

Penelope (Jenny) Quintana, PhD, MPH(Remote)

José R. Suárez, MD, PhD, MPH

### OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT:

Kimberly Gettmann, PhD, Deputy Director, Division of Scientific Programs

Rebecca Belloso, MPH, Health Program Specialist I, Safer Alternatives and Biomonitoring Section, Reproductive and Cancer Hazard Assessment Branch

Stephanie Jarmul, MPH, Research Scientist Supervisor, Section Chief, Safer Alternatives Assessment and Biomonitoring Section, Reproductive and Cancer Hazard Assessment Branch

Martha Sandy, PhD, MPH, Chief, Reproductive and Cancer Hazard Assessment Branch

Daniel Sultana, MS, Research Scientist III, Safer Alternatives and Biomonitoring Section, Reproductive and Cancer Hazard Assessment Branch

McKenna Thompson, MPH, Research Scientist I, Safer Alternatives and Biomonitoring Section, Reproductive and Cancer Hazard Assessment Branch

APPEARANCES CONTINUED

CALIFORNIA DEPARTMENT OF PUBLIC HEALTH:

Kathleen Attfield, ScD, Supervisor, Exposure Surveillance and Epidemiology Unit, Environmental Health Investigations Branch

Dina Dobraca, MPH, Research Scientist III, Exposure Surveillance and Epidemiology Unit, Environmental Health Investigations Branch

Ian Tang, PhD, Research Scientist IV, Environmental Health Investigations Branch

Jeff Wagner, PhD, Supervisor, Environmental Health Laboratory Branch

Nerissa Wu, PhD, MPH, Supervisor, Exposure Assessment Section, Environmental Health Investigations Branch

GUEST SPEAKER:

Mohammad Heidarinejad, PhD, PE, Illinois Institute of Technology

Ileanna Navarro, Central California Environmental Justice Network

ALSO PRESENT:

John Balmes, MD, University of California, Berkeley

Julie Von Behren, MPH, University of California, San Francisco

<u>INDEX</u>	<u>PAGE</u>
Welcome Kimberly Gettmann, PhD, Deputy Director, Division of Scientific Programs, OEHHA	1
Overview of the Meeting Amy Padula, PhD, MSc, Acting Chair, Scientific Guidance Panel (SGP)	5
Program Update Presentation: Nerissa Wu, PhD, California Department of Public Health (CDPH) Panel and Audience Questions Presentation: Ian Tang, PhD, CDPH Panel and Audience Questions Open Discussion and Input	8 18 23 30 46
Results and Impacts of the FRESSCA-Mujeres Project Presentation: Ileana Navarro, Central California Environmental Justice Network; Mohammad Heidarinejad, PhD, PE, Illinois Institute of Technology; Stephanie Jarmul, MPH, OEHHA Panel and Audience Questions Open Discussion Period and Input	51 82 88
Planning for 2026 SGP Meetings Presentation: Stephanie Jarmul, MPH, OEHHA Panel and Audience Questions	105 107
Open Public Comment Period	113
Wrap-up and Adjournment	114
Reporter's Certificate	115

PROCEEDINGS

DR. KIMBERLY GETTMANN: Good afternoon. I'd like to welcome the Panel members.

Good afternoon. I'd like to welcome the Panel members and the audience to the November meeting of the Scientific Guidance Panel for Biomonitoring California, more formally known as the California Environmental Contaminant Biomonitoring Program. Thank you all for joining us today. I am Kim Gettmann, OEHHA's Deputy Director for Scientific Programs.

The Panel last met on August 27th, 2025. The August meeting included updates on Biomonitoring California Program activities including a presentation on the BiomSPHERE Study results. The Panel also heard from two guest speakers on the use of silicone wristbands to assess personal chemical exposures, followed by a discussion on the use of the silicone wristbands to complement biomonitoring studies.

STEPHANIE JARMUL: Sorry, can you talk a little bit more into the mic. It's hard to hear.

DR. KIMBERLY GETTMANN: Is this better?

STEPHANIE JARMUL: Yes.

DR. KIMBERLY GETTMANN: Okay. Thank you.

Key discussion topics included: potential source of elevated inorganic arsenic in participants of the

1 California Regional Exposures Study in Los Angeles, or  
2 CARE-LA; analytical considerations when biomonitoring for  
3 microplastics; the utility of microsampling devices to  
4 collect blood for biomonitoring studies; the evaluation of  
5 results return materials that study participants receive.  
6 The Panel also discussed results from the BiomSPHERE  
7 study, including the higher levels of 2-naphthol, a  
8 metabolite of naphthalene, in BiomSPHERE participants  
9 compared to levels in the NHANES.

10 In the afternoon, the Panel discussed the  
11 possibility of using silicone wristbands to complement  
12 biomonitoring studies with guest speakers and Program  
13 staff. Key discussion topics on the wristbands included:  
14 the utility of wristbands of passive air samplers compared  
15 to other methods of passive air samp -- or air monitoring;  
16 best practices, ideal study design, and quality  
17 assurance/quality control procedures necessary to ensure  
18 accuracy of measurements of chemicals on wristbands;  
19 chemicals or chemical groups that are appropriate, or not  
20 appropriate, to measure using silicone wristbands, and  
21 variables that might influence chemical concentrations on  
22 the wristbands; ideal populations the Program should  
23 consider for use of silicone wristbands in biomonitoring  
24 studies; and participant's perspectives on receiving  
25 wristband results.

1           The summary and transcript of the meeting is  
2 posted on the August meeting page of the Program's website  
3 at biomonitoring.ca.gov. I'd like to announce Amy Padula  
4 will be our Acting SGP Chair for this meeting. I will now  
5 invite Panel members to introduce themselves by name and  
6 affiliation. Let's start with Jenny Quintana who is  
7 attending remotely. Jenny has been granted a reasonable  
8 accommodations to attend this meeting remotely and  
9 maintain with her camera off.

10           PANEL MEMBER QUINTANA: Hi, everybody, I'm  
11 Penelope or nicknamed Jenny, Quintana from the San Diego  
12 State University School of Public Health, Division of  
13 Environmental Health.

14           DR. KIMBERLY GETTMANN: Thank you.

15           I will now call on Panel members Lara Cushing and  
16 Ulrike Luderer from UC Irvine who will also be attending  
17 remotely.

18           PANEL MEMBER CUSHING: Hi. I'm Lara Cushing,  
19 Associate Professor of Environmental Health Sciences at  
20 UCLA.

21           PANEL MEMBER LUDERER: Hello. I'm Ulrike  
22 Luderer. I'm Professor of Environmental and Occupational  
23 Health at UC Irvine.

24           DR. KIMBERLY GETTMANN: Thank you. And now I  
25 will start at the end with Tom.

1           STEPHANIE JARMUL: Sorry. This is Stephanie  
2 Jarmul. Just to make an announcement that there are very  
3 few microphones. I apologize, so we'll need to pass them  
4 around and make sure you talk directly into them when  
5 you're speaking. Thank you.

6           PANEL MEMBER MCKONE: I'm Tom McKone, Professor  
7 Emeritus of Environmental Health Sciences at the  
8 University of California, Berkeley, School of Public  
9 Health.

10          DR. KIMBERLY GETTMANN: José.

11          PANEL MEMBER SUÁREZ: José Suárez, Associate  
12 Professor in the Herbert Wertheim School of Public Health  
13 and in the Department of Pediatrics at UC San Diego.

14          DR. KIMBERLY GETTMANN: Oliver.

15          PANEL MEMBER FIEHN: Oliver Fiehn, UC Davis. I'm  
16 a Professor in the Genome Center.

17          DR. KIMBERLY GETTMANN: Amy.

18          ACTING CHAIR PADULA: Amy Padula, Associate  
19 Professor in the Department of Obstetrics, Gynecology, and  
20 Reproductive Sciences at the University of California, San  
21 Francisco.

22          DR. KIMBERLY GETTMANN: Timur.

23          PANEL MEMBER DURRANI: I'm Timur Durrani. I'm  
24 Professor of Medicine at UCSF in the Division of  
25 Occupational, Environmental, and Climate Medicine.



1 DR. KIMBERLY GETTMANN: And Carl.

2 PANEL MEMBER CRANOR: Carl Cranor. I'm a  
3 distinguished Professor Emeritus at UC Riverside in  
4 Philosophy and Professor -- and distinguished Professor --  
5 not distinguished Professor -- Faculty Member of  
6 Environmental Toxicology at University of California,  
7 Riverside.

8 DR. KIMBERLY GETTMANN: Now, I'll hand off  
9 this -- hand off the meeting to Acting Panel Chair Amy  
10 Padula, who will provide more details about today's  
11 meeting.

12 ACTING CHAIR PADULA: Thank so much, Kim.

13 So as a reminder, for Panel members, please  
14 comply as usual with the Bagley-Keene Open Meeting  
15 requirements, that all discussions and deliberations of  
16 the Panel about subject matters at issue today need to be  
17 conducted during the meeting, not on breaks or with  
18 individual members of the Panel on- or off-line, including  
19 via phone, email, text, or chats. And Panel members who  
20 are attending remotely must visibly appear on camera, with  
21 the exception of Jenny, during the open portion of the  
22 meeting. And if you are unable to keep your camera on  
23 during the meeting, because it's technologically  
24 impractical, please make an announcement when you turn  
25 your camera off.

1           And additionally, if someone older than 18 is in  
2 the room with Panelists, who are attending remotely, you  
3 must disclose the presence of that person and their -- and  
4 their general relationship to you. So I just want to  
5 confirm with our Panelists that are online, Lara, Ulrike,  
6 and Jenny.

7           PANEL MEMBER CUSHING: (Nods head). (Thumb up).

8           PANEL MEMBER LUDERER: (Nods head). (Thumb up).

9           ACTING CHAIR PADULA: And as for an overview of  
10 the meeting, so we will hear an update on Program  
11 activities, including a presentation on persistent organic  
12 pollutant levels in Californians. The second portion of  
13 the meeting will include a joint presentation of  
14 collaborators -- collaborators on results and impacts of  
15 the Farmworker Women and Respiratory Exposure to Smoke  
16 From Swamp Cooler Air, the FRESSCA-Mujeres study. And  
17 finally, we'll hear about and have an opportunity to  
18 provide input on plans for the Scientific Guidance Panel  
19 meetings in 2026. And there will be time for questions  
20 from the Panel and audience after each presentation. And  
21 if SGP members wish to speak or ask a question, please  
22 raise your hand and I'll call on you. Jenny, you can  
23 speak up, since I'm not sure if I'll see your hand, but --  
24 and then you can ask your question or provide comment.

25           If online webinar attendees have questions or

1 comments during the question period after each talk, you  
2 can submit them via the Q&A feature of Zoom or by email to  
3 biomonitoring@oehha.ca.gov. We will not be using the chat  
4 function during this meeting, and please keep your  
5 comments brief and focused on the items under discussion.  
6 Relevant comments will be read aloud and paraphrased when  
7 necessary.

8           If align -- if online attendees wish to speak  
9 during the public period -- public comment period and  
10 discussion session, please use the "Raise Hand" feature in  
11 the Zoom webinar and Rebecca Belloso will call on you at  
12 the appropriate time. Please make sure that you join the  
13 webinar under the name you would like to be identified as  
14 when commenting, including if you would like to be -- if  
15 would like to remain anonymous. If you are attend --  
16 attending in person and wish to comment during the public  
17 comment period and discussion session, please come to the  
18 front or raise your hand, and I will call on you at the  
19 appropriate time.

20           For the benefit of the transcriber, we encourage  
21 you to clearly identify yourself before providing comment  
22 and write your name and affiliation on the sign-in sheet  
23 at the back of the room. However, there's no obligation  
24 to identify yourself and you are free to comment  
25 anonymously, if you wish. At the end of the meeting,

1 there will be time for open public comment period.

2 And I think now we will begin the first  
3 presentation. So Nerissa Wu will be the -- providing the  
4 first presentation. And she leads the Exposure Assessment  
5 Section in the Environmental Health Investigations Branch  
6 at the California Department of Public Health and the  
7 Program Lead for Biomonitoring California, and she will  
8 provide an update on the current Program activities.

9 (Slide presentation).

10 DR. NERISSA WU: All right. Thank you, Amy. And  
11 welcome everybody to our last Scientific Guidance Panel  
12 meeting of the year.

13 [SLIDE CHANGE]

14 DR. NERISSA WU: As usual, I will be giving the  
15 Program update covering the usual things that I talk  
16 about, surveillance, community-focused studies, laboratory  
17 work and our outreach and communications activities.

18 [SLIDE CHANGE]

19 DR. NERISSA WU: As you remember, we have a  
20 number of surveillance studies in the works. We have:  
21 CARE, the California Regional Exposures Study; STEPS, the  
22 Studying Trends in Exposure in Prenatal Samples; and  
23 MAMAS, Measuring Analytes in Maternal Archived Samples. I  
24 will actually only be touching on CARE and STEPS, because  
25 we have a more detailed presentation on MAMAS from the

1 presenter after me.

2 [SLIDE CHANGE]

3 DR. NERISSA WU: So news from the CARE study.  
4 Toki Fillman's work, in which she has presented on  
5 associations between PFAS in drinking water and serum PFAS  
6 levels, she's presented it here as a topic of discussion.  
7 This work has just been published in the Journal of  
8 Exposure Science and Environmental Epidemiology. It's  
9 open access and there's also a link available on our  
10 website if you are looking for that publication.

11 So in addition to that paper, we also have a  
12 two-page fact sheet, which gives a high level summary of  
13 the paper. And it's currently in our review chain, but we  
14 expect to have that released publicly soon.

15 [SLIDE CHANGE]

16 DR. NERISSA WU: Also, from the CARE Study, we  
17 talked about at our last meeting about new data on  
18 speciated arsenic and phenols for CARE-LA. We've been  
19 meeting with different researchers to discuss potential  
20 directions and approaches to research and to that -- and  
21 to exposure sources. We did also say that we're going to  
22 post the summary statistics for speciated arsenic and  
23 phenols. We haven't yet done so, because we noted a small  
24 calculation error on the slides. And so we'll be  
25 correcting that. We'll be posting the summary statistics,

1 and we'll also issue a new set of slides. The storyline  
2 doesn't change. It's a very numerical -- it's a very  
3 small numerical change, but we just want to make sure we  
4 have the most accurate numbers in our -- on our public  
5 website.

6           So we also have new laboratory results, speciated  
7 arsenic for CARE-2 study participants has just been  
8 received by EHIB. So we'll be conducting results return  
9 and summary statistics for those. And then, of course,  
10 that data can be folded in with the CARE-LA data, giving  
11 us more power to do statistical analyses.

12           We're also working on the phenols analyses for  
13 the CARE-2 participants and we expect to have those next  
14 year.

15                               [SLIDE CHANGE]

16           DR. NERISSA WU: And STEPS. And this is a study  
17 that used -- uses banked prenatal screening samples from  
18 the Genetic Disease Screening Program to determine  
19 population estimates of PFAS exposures over time. In  
20 Orange County - I think last time we talked about this -  
21 there were a number of samples that had to be rerun for QA  
22 issues. That's been completed, data is in review, and  
23 it's projected that we'll have the data finalized and  
24 reported to us in early December. And the lab is  
25 continuing to make progress with the Fresno County

1 samples. We're around 75 percent of the lab run. And we  
2 can't really talk a lot about the STEPS data yet, because  
3 it's still being finalized, but we're really excited to  
4 see the data, because it's going to help us understand,  
5 not only the temporal trends, but also help us understand  
6 what PFASs we need to keep our eyes on.

7 And in related news, this is not STEPS, but  
8 related to the issue of identifying the universe of PFASs  
9 of concern, we have sent samples from the Intra-Program  
10 Pilot study, the IPP, to Amina Salamova's lab for  
11 measurement of ultra-short chain PFASs, and we're  
12 expecting that data to be reported to us in early 2026 as  
13 well.

14 [SLIDE CHANGE]

15 DR. NERISSA WU: So turning to community-focused  
16 studies, I will be providing updates on these three  
17 community studies: ACE, the Asian/Pacific Islander  
18 Community Exposures Project; BiomSPHERE, the Biomonitoring  
19 component of the San Joaquin Valley Pollution and Health  
20 Environmental Research Study; and I'll be introducing  
21 CHAIRS, the Community Health and Air Quality Implications  
22 of Refinery Retirements in Los Angeles.

23 [SLIDE CHANGE]

24 DR. NERISSA WU: For ACE, you've heard Kelly Chen  
25 talk about her work, looking at the associations between

1 seafood consumption and PFAS serum levels. This has been  
2 submitted to the journal Exposure and Health. And we just  
3 heard on Monday that that manuscript has been accepted, so  
4 we expect that to be coming out in publication quite soon.

5 And our outreach and communication folks have  
6 been working on different ways to get this really  
7 important message out to broad audiences. So, as I  
8 mentioned, for Toki's paper, there will be a two-page  
9 summary of findings that will be distributed, as well as a  
10 postcard that's in lay language, very simple message that  
11 will go out to all study participants, but we'll also be  
12 distributing it at community events and to our community  
13 partners to pass along to their constituents.

14 There's also a suite of social media postings on  
15 PFASs generally, but more specifically about seafood and  
16 drinking water. And this approach to publication also  
17 applies to another paper we have coming out, that I don't  
18 have a slide on, because it's such recent news. I want to  
19 mention that Kathleen Attfield's paper on flame retardant  
20 levels following household furniture replacement has also  
21 been accepted for publication and will be out in early  
22 December.

23 And similar to ACE, we have a suite of  
24 communications materials coming out on that. So I should  
25 really acknowledge our Biomonitoring Outreach and



1 Communications group, which has been super, super  
2 productive and active and responsive to all of these --  
3 all of these findings and publications we have going out.

4 [SLIDE CHANGE]

5 DR. NERISSA WU: In BiomSPHERE, the focus has  
6 been on results return evaluation, which we talked a  
7 little bit about last time. We've been working with UC  
8 Merced and the Central California Asthma Coalition to  
9 assess our results return materials. We returned  
10 BiomSPHERE results over the summer. And then CCAC reached  
11 out to recruit participants to be part of one-on-one  
12 interviews about their experience with our results return  
13 materials. They then asked those interview participants  
14 to be part of a focus group to discuss both the existing  
15 paper materials that they had seen, but then also to look  
16 at the same type of materials, but presented through the  
17 Silent Spring DERBI platform.

18 They have just finished running three focus  
19 groups, two in Spanish, one in English, each with five to  
20 eight participants. So we don't have transcribed notes  
21 from that. We've just gotten some anecdotal findings from  
22 them. But, you know, the challenges we face that are  
23 inherent to biomonitoring, of course, are present in  
24 this -- in this evaluation as well. Our biomonitoring  
25 message is complex and it's hard to boil down to short

1 simple sentences, and results are not really a  
2 one-size-fits-all situation. We do hear from participants  
3 who want all the science, they want all the details, but  
4 we also are hearing from many participants that they  
5 really need a much more apparent readily accessible  
6 message back to them about their results.

7         So again, illustrating it's really important for  
8 us to continue to do these evaluations, and particularly  
9 to include a diverse group of participants, so that we are  
10 aware of and hearing about the challenges that they face  
11 when they see our materials.

12                     [SLIDE CHANGE]

13         DR. NERISSA WU: I'm going to briefly introduce  
14 the CHAIRS Study, Community Health and Air Quality  
15 Implications of Refinery Retirements in Los Angeles. This  
16 is a collaboration with UCLA with Lara, UC Irvine, and  
17 with Yale University. So the goal of this study is to  
18 assess the retirement of two petroleum refineries in Los  
19 Angeles, if it's associated with changes in exposure to  
20 air pollutants and various markers of health.

21         So the study will include Fresh Air wristbands.  
22 They are a little bit different than the silicone  
23 wristbands we talked about last time. There will be  
24 stationary monitors and collection of health indicators,  
25 including blood pressure, lung function, and airway

1 inflammation.

2           So the role of Biomonitoring California is to  
3 look at biomarkers of exposure. There will be up to 150  
4 residents of the surrounding communities, including Carson  
5 and Wilmington. Participants will provide four urine  
6 samples in total, two while the refineries are active, so  
7 study enrollment and sample collection is already  
8 underway. And then the refineries are scheduled to be  
9 shut down at the end of the year and then two more samples  
10 will be collected in fall 2026.

11           Right now, we're planning to have EHL analyze the  
12 urine samples for metals, along with speciated -- sorry,  
13 along with specific gravity and creatinine for dilution  
14 correction, and then aliquots will be stored for potential  
15 analyses of VOCs and PAHs. So that's just a very quick  
16 overview. There will be subsequent meetings when we talk  
17 more about the details of that study.

18                           [SLIDE CHANGE]

19           DR. NERISSA WU: And then just briefly, I've  
20 already mentioned our lab activities in conjunction with  
21 our projects. EHL is working to provide CARE-2 data. We  
22 just got our speciated arsenic, which is awesome, and  
23 phenols analyses are underway for the remaining 194  
24 participants of CARE-2.

25                           [SLIDE CHANGE]

1 DR. NERISSA WU: And ECL is focused on analyzing  
2 the STEPS samples. They still have Fresno and then the  
3 Los Angeles samples. And then we will be getting more  
4 samples from the 2024 births.

5 They also just completed proficiency testing for  
6 persistent organic pollutants, including PCBs, PBDEs and  
7 organochlorine pesticides. And then in addition to  
8 conducting analyses for existing studies, both labs are  
9 preparing to participate in the next round of the  
10 Intra-Program Pilot Study, which is designed to evaluate  
11 the use of microsamplers for PFASs and metals.

12 [SLIDE CHANGE]

13 DR. NERISSA WU: So I give this Program update a  
14 few times a year, and it often feels like I'm not doing a  
15 great job of conveying all the different activities that  
16 are going on and how much -- how much multi-tasking is  
17 going on among our staff. And this graph does not  
18 really -- I'm not sure it helps. It's a schematic of all  
19 the steps that a study might involve, but I think it's  
20 more helpful actually to look at it this way. And I have  
21 this animation, which I apologize if it's not really  
22 helping illustrate my point here.

23 [SLIDE CHANGE]

24 DR. NERISSA WU: Let me show it to you this way.  
25 I just wanted to convey all the various studies and the

1 types of Program activities that are taking place right  
2 now. We are involved with sample collection for CHAIRS  
3 and for IPP-8, looking at microsamplers. Our labs are  
4 involved with analyzing STEPS samples, as well as CARE-2,  
5 and they are preparing to receive samples from CHAIRS and  
6 IPP-8.

7 Our statisticians are working on results return  
8 and summary stats for the prior round of IPP, looking at  
9 PAHs, as well as speciated arsenic for CARE-2. And  
10 they're doing further statistical analysis related to  
11 CARE, MAMAS, SAPEP, BiomSPHERE, and FRESSCA-Mujeres. And  
12 there are multiple panels involved with each of those,  
13 which each involve literature search and consideration of  
14 what the exposure sources might be. And then, of course,  
15 as I mentioned, for all the publications or findings that  
16 come out of that work, our communications group is working  
17 on fact sheets and other public-facing materials related  
18 to all of these studies.

19 [SLIDE CHANGE]

20 DR. NERISSA WU: And then in addition, there are  
21 many activities that are related to moving the science of  
22 biomonitoring forward. That's not necessarily attached to  
23 a particular project. So we have development of  
24 laboratory methods, evaluation and standardization of  
25 statistical methods, creation of templates for

1 communication materials across the board, review of  
2 scientific literature, and assessment of field methods.  
3 And all of this is again moving the science of  
4 biomonitoring forward, so that we can incorporate it into  
5 future biomonitoring studies.

6 [SLIDE CHANGE]

7 DR. NERISSA WU: And none of it gets done without  
8 this awesome group of people.

9 [SLIDE CHANGE]

10 DR. NERISSA WU: And that ends what I have for  
11 you today.

12 ACTING CHAIR PADULA: So we can take questions  
13 from the Panel to start and this is just an opportunity  
14 for clarifying questions. There will be a discussion  
15 later.

16 PANEL MEMBER MCKONE: Very interesting. I have  
17 some questions about the refinery studies. So there's two  
18 refineries that are shutting down. You're going to do  
19 some samples now, while they're still operating and then  
20 after they're closed, right?

21 DR. NERISSA WU: Yes.

22 PANEL MEMBER MCKONE: Is there an opportune -- so  
23 I assume the closure will involve remediation. A lot of  
24 refineries have a lot of contaminated materials on the  
25 site that actually slowly outgas some of the things

1 that -- is there a way then to go back even a couple years  
2 later, when they've fully remediated the site and  
3 eliminated some of the, like, smoldering residues?

4 DR. NERISSA WU: Good point. Well, I actually  
5 will call on Lara or Stephanie to answer that.

6 STEPHANIE JARMUL: Great question, Tom. Well, we  
7 are planning on going back next fall to collect additional  
8 samples. And depending on funding, we are hoping to add a  
9 third year onto the study to come back the following year  
10 again to see if any of the levels have changed subsequent.

11 PANEL MEMBER MCKONE: While you're there, I have  
12 one more.

13 STEPHANIE JARMUL: Okay.

14 PANEL MEMBER MCKONE: So refineries have  
15 continuous emissions, but they're also notorious for  
16 flares, which are off-normal and, in theory, they're  
17 not -- they don't get permits for flares, because it's a  
18 safety -- you know, they have to burn gases. So my  
19 understanding is actually some significant emissions that  
20 come out of flares, but if you're doing a urine sample,  
21 it's just a snapshot. Is there -- I mean, again, has  
22 anyone given thought to like a biomarker that would  
23 reflect a longer term cumulative exposure? I don't know  
24 what that would be. It's the magic exposome.

25 STEPHANIE JARMUL: I mean maybe if we were able

1 to collect blood, but I -- that is not the current plan  
2 for the study. You know, metals that we're measuring,  
3 they can have lot longer half-lives. Might be indicative  
4 of longer term exposures, but for the PAHs and VOCs, what  
5 we're measuring, that is more like a cross-sectional point  
6 in time.

7 PANEL MEMBER MCKONE: Okay.

8 STEPHANIE JARMUL: Yeah, but I know there was a  
9 recent flare-up in one of the refineries in LA I think a  
10 few months ago. So hopefully, there's no more, but -- and  
11 hopefully we don't cap -- we capture it if there is one,  
12 but yeah.

13 PANEL MEMBER MCKONE: Thank you. No, very  
14 interesting study.

15 ACTING CHAIR PADULA: Any other questions?

16 I actually have one, if that's okay. I wanted to  
17 know -- I imagine this will get discussed maybe more at  
18 another time, but the Fresh Air bands, I'm just wondering  
19 how they differ from the silicone in terms of what they're  
20 measuring or how long they're measuring it.

21 STEPHANIE JARMUL: So the -- and Lara, correct me  
22 if I'm wrong, but the Fresh Air wristbands are different,  
23 in that it's more like a passive air sampler, so they're  
24 not actually, you know, cutting and testing the silicone  
25 itself. Yes, it's technically a silicone wristband, but



1 there's actually a little mini-sampling device on it,  
2 which is more catered to capture air exposures  
3 particularly, instead of air and dermal that the wristband  
4 would.

5 ACTING CHAIR PADULA: Thank you.

6 DR. NERISSA WU: You could just stay up here.

7 STEPHANIE JARMUL: I know.

8 ACTING CHAIR PADULA: Jenny -- go ahead please,  
9 Jenny.

10 PANEL MEMBER QUINTANA: Hi. I just had a  
11 clarifying question about the CHAIRS-LA study. What were  
12 the inclusion or exclusion criteria for the participants?

13 STEPHANIE JARMUL: Lara, do you want to take that  
14 one more specifics?

15 PANEL MEMBER CUSHING: Sure. They have to be  
16 adults, 18 and over. Just because we didn't have the  
17 resources to do justice to a children's study, we were  
18 pretty limited in resources, so we decided to focus on  
19 adults. They have to live within a couple of kilometers  
20 of the refinery property boundary. They have to have  
21 lived at their -- in the neighborhood for at least a year  
22 and have no plans to move in the next year, and they  
23 cannot be tobacco smokers. And that was primarily because  
24 that would probably, really drive the -- you know, the  
25 personal exposure measures if we were to include tobacco

1 smokers. And they had to speak English, Spanish, or  
2 Tagalog.

3 PANEL MEMBER QUINTANA: So they couldn't be  
4 smokers or live with smokers?

5 PANEL MEMBER CUSHING: They could live with  
6 smokers.

7 PANEL MEMBER QUINTANA: They could live with  
8 smokers?

9 PANEL MEMBER CUSHING: Yeah, but they couldn't  
10 be --

11 PANEL MEMBER QUINTANA: But you would have that  
12 information captured, right?

13 PANEL MEMBER CUSHING: Yes.

14 PANEL MEMBER QUINTANA: Okay. Because that might  
15 affect things. And also I was just curious if you either  
16 ask about this or had a requirement that they not commute  
17 a long way, or spend a certain amount of time at home, or  
18 was that just something you capture with questionnaires in  
19 terms of their commuting behavior or on-road exposures?

20 PANEL MEMBER CUSHING: We capture it in the  
21 questionnaire. It's not an exclusion criteria. Part of  
22 the -- yeah, I think just mostly for practicality reasons,  
23 logistical reasons. So we will have some commuters in the  
24 population for sure.

25 PANEL MEMBER QUINTANA: Thank you.

1           STEPHANIE JARMUL: And this is Stephanie. For  
2 the urine samples at least, we'll be collecting the first  
3 morning voids at least, which should be more indicative of  
4 their at-home exposures.

5           PANEL MEMBER QUINTANA: Thank you.

6           ACTING CHAIR PADULA: Okay. Thank you so much,  
7 Nerissa.

8           Oh, are there any more questions?

9           Okay. Okay. So -- in the next agenda item, we  
10 will be hearing from Ian Tang. Ian Tang is a Research  
11 Scientist in the Environmental Health Investigations  
12 Branch at CDPH and he will give a presentation on  
13 persistent organic pollutants, or POPs, levels in  
14 Californians.

15           (Slide presentation).

16           DR. IAN TANG: Thank you for the introduction.  
17 I'm Ian, and today I'll be talking about persistent  
18 organic pollutant levels, and many of the studies from  
19 Biomonitoring California. And specifically, we're trying  
20 to get to the question of how we ask, "Shouldn't  
21 hexachlorobenzene be decreasing in Californians?" And a  
22 version of this presentation was given at the Joint  
23 International Societies of Exposure Science and  
24 Environmental Epidemiology. And that was in Atlanta  
25 earlier this year.

1 [SLIDE CHANGE]

2 DR. IAN TANG: So just to recap, persistent  
3 organic pollutants are persistent due to their strong  
4 halogenated bonds with carbon. They bioaccumulate due to  
5 their lipophilic properties and they're also toxic to  
6 multiple organ systems. They include organochlorine  
7 pesticides, such as the ones listed here, beta-HCH, DDT,  
8 DDE, HCB or hexachlorobenzene, trans-nonachlor,  
9 oxychlordane, and also polychlorinated biphenyls.

10 [SLIDE CHANGE]

11 DR. IAN TANG: So widespread use of POPs occurred  
12 from the 1940s to the 1970s. HCB was introduced in the  
13 19 -- in 1945. And around 1970 -- in the 1970s  
14 restrictions began for POPs and HCB was regulated in the  
15 United States in 1984.

16 By 2004, POPs were regulated by the Stockholm  
17 Convention. And in 2006, Biomonitoring California began  
18 and also started conducting studies.

19 [SLIDE CHANGE]

20 DR. IAN TANG: So last year, you all heard that  
21 participants in MAMAS 1 had HCB levels around six to eight  
22 nanograms per gram, but subsequent MAMAS in 2000 -- 2015  
23 and 2016 showed that there was an increase to about above  
24 10 nanograms per grams per lipid. And there was also a  
25 hundred percent detection frequency for HCB.

1           So we looked at all the other POPs and found that  
2 overall they're decreasing with each subsequent MAMAS.  
3 And so this led us to do some investigations on HCB, which  
4 is one of the most persistent of the persistent organic  
5 pollutants and the half-life is about 6 to 11 years,  
6 depending on the media. It's also used as a fungicide  
7 primarily, but it can also be a byproduct of other  
8 chlorinated solvents, such as PCE and TCE.

9                               [SLIDE CHANGE]

10           DR. IAN TANG: So given that POPs have been  
11 restricted for almost 20 years around the world and over  
12 40 years in the United States, I think that we would  
13 expect to see a decline in POPs over time. The fact that  
14 we don't see this with MAMAS, led us to try and look at  
15 this trend across all Biomonitoring California studies.  
16 And so the hypothesis that we were looking at is are POPs  
17 actually decreasing?

18                           [SLIDE CHANGE]

19           DR. IAN TANG: So we combined all of our  
20 student -- studies together into one data set and  
21 restricted it to women of reproductive age just to match  
22 what we had in MAMAS. The total N was 649 women and a  
23 third was Hispanic and the mean age was 30 years old. So  
24 here's a table of all of the studies that we've conducted  
25 where we have POPs data. And luckily, they've been all

1 analyzed by DTSC, so it's all the same lab. And we -- the  
2 studies span from 2010 to 2017. And there's some overlap  
3 between some studies.

4 So these -- this subset includes mothers,  
5 firefighters, Kaiser Permanente members, and also prenatal  
6 screening participants across different regions of  
7 California.

8 [SLIDE CHANGE]

9 DR. IAN TANG: We analyzed all of the different  
10 OCPs, as I mentioned earlier. And we also looked at PCB  
11 153, since it's one of the most abundant PCB congeners.  
12 To look at the time trends, we used linear regression with  
13 the sample year of collection used to predict the  
14 log-transformed analyte concentration and we adjusted for  
15 age and race/ethnicity.

16 POPs were lipid-normalized. We also set the  
17 level of detection to be standardized across all the  
18 studies to the highest one and beta coefficients were  
19 back-transformed to percent change, and we also looked at  
20 Spearman correlation coefficients to examine possible  
21 monotonic trends.

22 [SLIDE CHANGE]

23 DR. IAN TANG: So here are the geometric means by  
24 year, excluding PBDE -- p,p'-DDE just because the  
25 magnitude is large. You can see that HCB here in gold

1 appears to be increasing with time, while all of these  
2 other POPs are decreasing or have low concentrations.

3 [SLIDE CHANGE]

4 DR. IAN TANG: And just to show DDE it's also  
5 sort of decreasing by time.

6 [SLIDE CHANGE]

7 DR. IAN TANG: And here are the adjusted percent  
8 changes of POP concentration by year. I also have the  
9 geometric means listed over there. P,p'-DDE has the  
10 highest geometric mean of 39.9 nanograms per gram lipid.  
11 And HCB has the second highest at 10.5, while all the  
12 other POPs are around two to three nanograms per gram.

13 The adjusted percentage change I've highlighted  
14 in green, indicates a decreasing percent change. And as  
15 you can see all these POPs are decreasing by year, except  
16 for hexachlorobenzene. We had crude estimates and they  
17 were not very different from these adjusted estimates.

18 [SLIDE CHANGE]

19 DR. IAN TANG: So there are several limitations  
20 to this analysis. We used different populations from  
21 different geographic regions. And we're really not able  
22 to differentiate the effects of study from year. And  
23 also, we had a low number of individuals in some years.  
24 We conducted several sensitivity analyses. We looked at  
25 the trends among men and women, women of all ages. We

1 also excluded individuals of high LODs. And we also used  
2 a meta-regression to control for study heterogeneity. We  
3 found out these estimates were generally similar to  
4 these -- this primary analysis. And in the future, we  
5 hope to add one more study, which would hopefully double  
6 our sample size and also adjust for more confounders, such  
7 breast feeding, pregnancy, and nativity.

8 [SLIDE CHANGE]

9 DR. IAN TANG: So, what's going on? Our studies  
10 sort of indicated geometric mean, about 10 nanograms per  
11 gram lipid. We compared this to NHANES and found that HCB  
12 levels, depending on the population, sort of varies around  
13 6 to 12 nanograms per gram. And this table shows the  
14 weighted arithmetic mean for NHANES Hispanic females.

15 A subsequent study looking at NHANES cycles from  
16 2005 to 2015 cycles found a least square geometric mean  
17 range of 8.9 to 9.6 nanograms per gram lipid. And they  
18 only found a negative 1.6 percent change for HCP -- HCB  
19 across all of these cycles, whereas the other POPs had a  
20 percent change of about 8.

21 And just going through this, other populations  
22 such as in Belgium, Atlanta, a controlled set for an ALS  
23 case control study found that the median or geometric mean  
24 was about 7 to 13 nanograms per gram lipid.

25 [SLIDE CHANGE]



1 DR. IAN TANG: So the next question is where are  
2 the possible exposures that could be leading to HCB  
3 plateauing in humans? HCB has been detected in some of  
4 the foods, but the residues tend to be very low. There's  
5 a possibility that HCB in the ocean or in the soil is  
6 being disrupted and revolatilizing into the atmosphere,  
7 leading to re-emissions. There's no -- really no known  
8 hazardous waste incinerator or industry that produces HCB  
9 in California, but we can't rule out that there are  
10 industrial sources from other parts of the world that  
11 could be transported through long-range transport.

12 Lastly, HCB can be a byproduct of the other  
13 chlorinated solvents. And also, there's been a lot of  
14 historical use, such as it's -- it was used as a wood  
15 preservative, rubber -- and rubber, aluminum, magnesium  
16 and also a dye.

17 [SLIDE CHANGE]

18 DR. IAN TANG: So the literature on HCB in the  
19 environment is also compelling. A lot of studies have  
20 shown that it's either staying stable or increasing. One  
21 of them is shown here where there were air monitors in the  
22 North American Great Lakes. And you can see HCB in the  
23 bottom right-hand corner seems to be stable, while all the  
24 other persistent organic pollutants are decreasing over  
25 time. And this timeline was from 1990 to 2015.

1 Another study looked at air monitors comparing  
2 HCB levels from 2016 and 2006. And so these circles on  
3 the maps represent that ratio of 2016 over 2006, and over  
4 68 percent of these sampling sites had a ratio above 1.2.  
5 And that large black circle on the map indicates it's in  
6 the country of Latvia, and there have been bio -- have  
7 been studies in the Baltic Sea also showing that HCB  
8 trends were either stable or increasing.

9 [SLIDE CHANGE]

10 DR. IAN TANG: So we have a lot of questions,  
11 more so than we have answers. Are HCB concentrations  
12 plateauing? Is this because of a new or exist -- existing  
13 exposures? Are these a level of concern? And this really  
14 shows that HCB can still -- because it's a persistent  
15 organic pollutant, it can still be affecting our society,  
16 even though it's been regulated for so long. And even if  
17 it's being emitted somewhere, it could still end up  
18 everywhere.

19 And it also shows how important our surveillance  
20 of POPs are given the restrictions. And if anyone has any  
21 clues on how to identify possible sources, that would be  
22 great.

23 [SLIDE CHANGE]

24 DR. IAN TANG: And so I'd like to acknowledge all  
25 the collaborators, funding sources, and our participants

1 over the years.

2 ACTING CHAIR PADULA: Any questions from the  
3 Panel?

4 PANEL MEMBER FIEHN: Yeah. That's fascinating or  
5 scary, but it's certainly interesting. Now, I understand  
6 that your study was focused on females because of the  
7 MAMAS, the samples that you had, but what about other  
8 people? Have other people also looked in men? There must  
9 be other, you know, literature where people try to look at  
10 historic trends?

11 DR. IAN TANG: There are a few out there and  
12 they've also included men and there's also been a few  
13 studies on children as well. And it appears that the  
14 trend is similar in terms of HCB staying stable. We've  
15 talked to some of our NHANES colleagues and they also see  
16 the same trends in both men and women, yeah.

17 PANEL MEMBER FIEHN: Yeah. And a follow-up. I  
18 mean hexachlorobenzene is, of course, you know, well, all  
19 the carbons are satisfied with chlorine. Is that a  
20 physical/chemical reason why maybe it's just much more  
21 stable?

22 DR. IAN TANG: It is quite stable. I'm not sure  
23 if I can answer any more about that. Does anyone have any  
24 thoughts?

25 PANEL MEMBER FIEHN: Okay.

1           PANEL MEMBER McKONE: It's very stable, but it's  
2 also very lipophilic. And there are other compounds that  
3 have shown this kind of long term-behavior, the  
4 dioxin-like compounds. And you cited Ron Hites. He had  
5 actually some really interesting papers about retention of  
6 dioxin-type compounds in all kinds of lipid membranes.  
7 And I suspect this might be doing the same thing. What  
8 happens is it's very lipophilic, it's very persistent. It  
9 goes into anything that's lipid and then slowly outgases  
10 as the -- I mean, the -- it goes into the atmosphere and  
11 then it maintains a constant concentration in the  
12 atmosphere, and then the atmosphere feeds the food chain.

13           DR. IAN TANG: Right.

14           PANEL MEMBER McKONE: I suggest, if you want some  
15 insight, you might want to talk to Matt MacLeod at  
16 Stockholm University. He actually gave us a  
17 presentation -- when did Matt talk to us?

18           AUDIENCE MEMBER: Two years ago?

19           PANEL MEMBER McKONE: I mean, anyway. He's -- I  
20 mean he knows OEHHA, but he's done a lot of work on  
21 persistent pollutants, and global transport, and  
22 re-emission -- emission re-emission cycles, and how like  
23 lipid and soil feeds food chains on a continuing basis.

24           DR. IAN TANG: Right.

25           PANEL MEMBER McKONE: So you might want to just

1 see if he has some insight about this. He's probably -- I  
2 mean, there are others, but I think he's one of the best  
3 people out there doing this kind of work.

4 DR. IAN TANG: Thank you so much. We'll reach  
5 out.

6 ACTING CHAIR PADULA: And I just want to open it  
7 up to a discussion for both of the presentations, both  
8 Nerissa's and Ian's -- oh, and sorry. Go ahead first,  
9 Lara.

10 PANEL MEMBER CUSHING: Thanks. Yeah. You  
11 mentioned wanting to control for nativity in some of the  
12 additional analysis you'd like to do. And I was just  
13 curious, do you know how -- what the proportion of  
14 immigrants is in your pooled sample and how it might have  
15 changed over time? I'm not sure if that could be a  
16 factor, but I know, you know, the year when HCB was banned  
17 in different countries, you know, differed.

18 DR. IAN TANG: Um-hmm, right.

19 PANEL MEMBER CUSHING: So I was just wondering if  
20 you had taken a look at the distribution of immigrants  
21 over time in the pooled sample?

22 DR. IAN TANG: Yeah. That's an excellent  
23 question. I can't -- I don't know what the distribution  
24 on the top of my head is. We're still in the process of  
25 harmonizing all this data in terms of across all the

1 studies. However, some of these studies are -- for  
2 instance, in some of the BEST studies, are in the Central  
3 Valley, and a lot of those individuals are immigrants.  
4 And so I would -- I think it's a little bit different for  
5 each study, but, yeah, we'll definitely take a look at the  
6 distribution and try to understand it a little bit better.

7 ACTING CHAIR PADULA: Go ahead, Jenny.

8 PANEL MEMBER QUINTANA: Hi. Thank you. And I  
9 did have the same question as Lara and either country of  
10 origin or where they were born, because I think also their  
11 mother's body burden might affect the children. But  
12 specifically, I'm wondering, did you have data on BMI or  
13 obesity levels? I'm -- I know that I tried look at the  
14 literature on obesity and POPs, and it's confusing. It's  
15 not a straightforward story to me at least. I mean, I was  
16 trying to wade through it.

17 And I guess a related question for the Panel  
18 looking forward, I'm kind of curious how Ozempic or those  
19 kind of drugs might affect our biomonitoring? I know that  
20 rapid weight loss, you know, does tend to flood the body  
21 with some of the stored pollutants. And so just looking  
22 forward, maybe that would be something to look at as well.  
23 So that's a bunch of questions in one. Thank you.

24 DR. IAN TANG: That is a really interesting point  
25 about Ozempic and how that might sort of remobilize POPs,

1 and then think it's something we can capture in early --  
2 in surveys. But, yeah, in terms of your previous question  
3 on BMI, some of our studies, we do have BMI. However,  
4 because the most recent studies that we have is based on  
5 MAMAS, and they are coming from the Biobank, they're  
6 prenatal screen samples, we don't necessarily have good  
7 data on everyone for that.

8 So it is something that we're considered --  
9 considering. Maybe we can run a sensitivity analysis  
10 subsetting it among individuals where we do have BMI.  
11 But, yes, an important point. Thank you.

12 PANEL MEMBER QUINTANA: Thank you.

13 ACTING CHAIR PADULA: Go ahead, please. And  
14 please introduce yourself, if you could.

15 DR. MARTHA SANDY: Sure. Martha Sandy, OEHHA.

16 I wonder, Ian, if you could go back and show us,  
17 you had a slide on your sensitivity analyses and pulling  
18 in all men and women. And then maybe one of the slides  
19 looking at other POPs and just read for us what they were,  
20 because to get to Dr. McKone's point and the question  
21 about what's special about hexachlorobenzene. Some of the  
22 other POPs I think are also fully chlorinated, or  
23 brominated, or we could think about PCBs, and PBDEs, and  
24 things like that.

25 ACTING CHAIR PADULA: Would you go back?

1 DR. IAN TANG: So it was the sensitivity analyses  
2 and then maybe this slide?

3 DR. MARTHA SANDY: The -- I think you had some  
4 nice graphs time trends too.

5 DR. IAN TANG: Oh, I see.

6 DR. MARTHA SANDY: But the sensitivity analysis  
7 with the -- all the different groups, you tried -- because  
8 you were looking at women of child-bearing age, and then  
9 you looked more broadly.

10 DR. IAN TANG: Right.

11 DR. MARTHA SANDY: To go over that again just to  
12 pull that up.

13 DR. IAN TANG: I see. Okay. So I have the  
14 results of those, if that's --

15 DR. MARTHA SANDY: Or just to remind us what you  
16 did.

17 DR. IAN TANG: Yeah. Okay. Sure. Yeah, for the  
18 sensitivity analyses, we combined both men and women  
19 across all of our different studies together. We also --  
20 because in our -- in this -- in the analyses showed here,  
21 we also restricted to women of reproductive age. We  
22 expanded it out to all women. And also because the MAMAS  
23 had different -- they had higher LODs, because they were  
24 using banked serums, the LOD is a little bit higher. And  
25 so, if we were to sort of model it, it would change the



1 shape of the regression. So we wanted to restrict and  
2 standardize the LODs across all of the different -- all  
3 the different studies and also see what happens if we just  
4 excluded the women who had the highest LODs to see if that  
5 was biasing the results or the trend that we're seeing.

6 With meta-regression, we also looked at it -- the  
7 geometric mean by studies. And so this is a way to  
8 control for the study heterogeneity that we have, so it's  
9 expanding. It's coming from the individual level back out  
10 to the population level. And so the magnitudes are much  
11 more different, they're much larger, and a little bit more  
12 unstable. But I think that that's something we would  
13 expect to see when we're able to account for this study  
14 variability.

15 Does that answer your question?

16 DR. MARTHA SANDY: Yes.

17 DR. IAN TANG: Okay. Yes. Hi.

18 PANEL MEMBER SUÁREZ: José Suárez, UC San Diego.

19 Thank you all for the presentation. I just had a  
20 couple of questions about your -- the newer methodology  
21 for calculating the percent change --

22 DR. IAN TANG: Um-hmm.

23 PANEL MEMBER SUÁREZ: -- if I can dive in a  
24 little bit deeper with that.

25 DR. IAN TANG: Yeah. So we calculated the beta

1 and this was using the log-transformed concentrations.  
2 And so we back-calculated it using exponentiation of the  
3 beta minus 1 times 100.

4 PANEL MEMBER SUÁREZ: I guess my question is, so  
5 if we -- if you wouldn't mind showing us the -- let me see  
6 the slide -- let's see, I think it's slide number 8 is the  
7 one that lets us --

8 DR. IAN TANG: Okay.

9 PANEL MEMBER SUÁREZ: -- take a look at things a  
10 little bit, right?

11 So we're looking at the trends there, excluding  
12 DDE, because the magnitudes --

13 DR. IAN TANG: Um-hmm.

14 PANEL MEMBER SUÁREZ: -- are way higher. That's  
15 the next chart. Overall, from your analyses, you're  
16 showing that they were decreasing, except for  
17 hexachlorobenzene, right?

18 DR. IAN TANG: Um-hmm.

19 PANEL MEMBER SUÁREZ: If we're looking at the  
20 figure here though however, it's kind of hard to look at  
21 that, but if you -- it's very hard to look, but  
22 oxychlordan and p,p'-DDT, which are the two lines in the  
23 bottom --

24 DR. IAN TANG: Um-hmm.

25 PANEL MEMBER SUÁREZ: -- they actually seem to be

1 increasing over time once you look very carefully at that.

2 DR. IAN TANG: Yeah.

3 PANEL MEMBER SUÁREZ: And part of where I'm going  
4 to with this is, so you calculated the percent change from  
5 2010 through 2016, right, that's the percent change?

6 DR. IAN TANG: Yes. Yeah.

7 PANEL MEMBER SUÁREZ: And so part of the concern  
8 here too is that in 2010, there are only 34 participants  
9 that have a measurement, right?

10 DR. IAN TANG: Yeah.

11 PANEL MEMBER SUÁREZ: So how much you can  
12 generalize or how stable you think those concentrations  
13 are, are probably lower than once you start going towards  
14 2015-2016, where you reached 236 and 206, right?

15 DR. IAN TANG: Um-hmm.

16 PANEL MEMBER SUÁREZ: And the other part worth  
17 taking a look at too is when you're calculating percent  
18 change, especially with variables that are highly skewed,  
19 right? So these -- I presume that are pretty skewed, as  
20 they tend to be, right? Then, when they're in the very  
21 low concentrations, even tiny changes can result in very  
22 substantial percent change. So you must have had to, at  
23 some point, restrict outliers to be able to come up with  
24 numbers that are not, you know, 300 percent decreases, 500  
25 percent decreases.

1 DR. IAN TANG: Uh-huh.

2 PANEL MEMBER SUÁREZ: So, in other words, I would  
3 suggest also looking at the absolute difference --

4 DR. IAN TANG: Sure.

5 PANEL MEMBER SUÁREZ: -- by the time period. And  
6 then something worth considering it, is it worth it to  
7 compare back to a sample with only 34 observations in it  
8 or can you start maybe grouping them and say, well, the  
9 2020 and the 2012 one, you group all of those as your  
10 baseline category.

11 DR. IAN TANG: I see.

12 PANEL MEMBER SUÁREZ: And from there, you can  
13 start doing the comparisons and maybe you can start  
14 getting a little more stability with your -- with the  
15 estimates.

16 DR. IAN TANG: Right. Yeah. I think that's a  
17 great point on the starting value being N equals 34. We  
18 are trying to get an additional study around the same  
19 time, specifically the California Teachers Study, which  
20 will increase our sample size up I think by a thousand.  
21 So that hopefully should address some of the concerns  
22 there. But I do take your point. I think the idea of  
23 combining the -- like earlier studies together to gain a  
24 little bit more numbers is a good idea. And yeah, it's an  
25 -- it's an interesting point trying to think of what a --

1 what the percent change would represent, because I think  
2 we were thinking that the slight increase over time that  
3 we see could be because of the level of detection  
4 differences. But, yeah, it's -- we'll look into it some  
5 more. Yeah. Thank you. This is a lot of feedback --  
6 good feedback.

7 PANEL MEMBER SUÁREZ: And technically, this  
8 should coincide, right?

9 DR. IAN TANG: Um-hmm.

10 PANEL MEMBER SUÁREZ: So even with these -- it's  
11 hard to see it in this figure.

12 DR. IAN TANG: Um-hmm.

13 PANEL MEMBER SUÁREZ: I had to like really zoom  
14 in quite close to see that there's slight increases in  
15 those two, right?

16 DR. IAN TANG: Um-hmm. Yes.

17 PANEL MEMBER SUÁREZ: So of -- I think just some  
18 methodological adjustments there --

19 DR. IAN TANG: Sure.

20 PANEL MEMBER SUÁREZ: -- I think might be good.

21 DR. IAN TANG: Okay.

22 PANEL MEMBER SUÁREZ: But look at the absolute as  
23 well.

24 DR. IAN TANG: Yeah.

25 PANEL MEMBER SUÁREZ: -- to see if that starts

1 matching up a little bit closer to this.

2 DR. IAN TANG: Okay. Yeah, thank you so much.

3 ACTING CHAIR PADULA: Any additional questions?

4 I just have one additional follow-up question.

5 It sounds like the upcoming subanalyses by parity and  
6 things will be, of course, interesting. I was also  
7 wondering, since some of those women were -- some of the  
8 cohorts were pregnant and some of them were not, have  
9 you -- have you lumped the pregnant and non-pregnant ones  
10 yet or -- I mean, I know most of them are MAMAS, but  
11 there's one other.

12 DR. IAN TANG: Yeah. We've lumped them all  
13 together in this case, yeah. For example, in -- women of  
14 reproductive age who were not pregnant would be included  
15 in this, yes. Yeah.

16 PANEL MEMBER SUÁREZ: It's fascinating and I have  
17 kind of a follow-up question of that, which is breast  
18 feeding --

19 DR. IAN TANG: Uh-huh.

20 PANEL MEMBER SUÁREZ: -- do you happen to have  
21 information about breast feeding duration or breast  
22 feeding or not, given that there's a good amount of data  
23 showing that a lot of these POPs can be excreted by breast  
24 milk?

25 DR. IAN TANG: Exactly. Yes. So that is data

1 that we have collected and we've harmonized. However,  
2 they're not available for everyone in MAMAS, and also some  
3 of the clinical data for some of our cohorts, we don't  
4 have that data. So if we were to actually do this  
5 analysis, adjusting for more confounders, then we would  
6 expect the sample size to decrease just because of the  
7 data availability.

8 PANEL MEMBER SUÁREZ: Yeah, I'd be very curious  
9 though I wonder -- I wonder how many of these studies -- I  
10 mean, it's not a huge sample size --

11 DR. IAN TANG: Yeah.

12 PANEL MEMBER SUÁREZ: -- but if there's -- I'll  
13 just be personally very interested in seeing duration of  
14 breast feeding and how that correlates.

15 DR. IAN TANG: Yeah. Definitely, yeah. Yeah, we  
16 -- well we have, yeah, some of that data. So it's very  
17 exciting. We're so -- I think we're waiting for the CTS  
18 data to come in and then see how we can reanalyze the  
19 data.

20 There -- at ISEE/ISES, there was also a couple of  
21 folks who wanted to collaborate and maybe add in more  
22 cohorts. We've been also considering that as well just to  
23 see if we can just gain more power and more people in each  
24 year. So we're still thinking about how to do that, since  
25 there's like different labs, and different techniques, and

1 different populations and stuff.

2 DINA DOBRACA: Can I ask the SGP a question?

3 ACTING CHAIR PADULA: Yes.

4 Who are you?

5 DINA DOBRACA: Oh, my name is Dina Dobraca. I'm  
6 a Research Scientist with the California Department of  
7 Public Health. I was wondering there was one PCB used in  
8 this analysis as like the -- expected to be most detected,  
9 persistent PCB, but to get to the point that was brought  
10 up previously about how chlorinated HCB is, are there any  
11 other PCBs or dioxin-like compounds that one would like to  
12 see, if we could get that data?

13 PANEL MEMBER SUÁREZ: Is the question going  
14 towards the -- well, I think the underlying part --

15 AALEKHYA REDDAM: Sorry. Can you identify  
16 yourself for the transcript?

17 PANEL MEMBER SUÁREZ: Oh, sure. José Suárez. So  
18 part of this too is HCB has a substantially longer  
19 half-life than the other ones -- than most of them, not  
20 all of them. It's not the one that has the longest --  
21 probably of the ones you measured, the longest, but among  
22 the longest half-lives, right?

23 So I wonder if you're -- do you think your  
24 question goes in that direction? Should we -- are there  
25 other more persistent pesticides or, excuse me, chemicals



1 that should be measured that were very prevalent at some  
2 point and maybe we should be monitoring that a little bit  
3 better?

4 DINA DOBRACA: Yeah. I'm basically asking the  
5 SGP for the recommendation of if we have the data or could  
6 get the data, what would they recommend?

7 PANEL MEMBER McKONE: Can I follow-up? Tom  
8 McKone, Panel. They have to be careful. It isn't just  
9 persistent. And this is where it helps to talk to  
10 somebody who does fate modeling or fate analysis, because  
11 it isn't just the half-life. It is the vapor pressure,  
12 the solubility, and the lipid -- I mean, the water  
13 solubility, air solubility, vapor pressure, and how these  
14 play together and where the reaction takes place. So if  
15 something is -- degrades in water, but is really not  
16 soluble. It's not in water. It's how much gets into --  
17 so again, you can't really understand this, because we've  
18 got about at least six different parameters that you have  
19 to put together.

20 And that's why I say people like Matt MacLeod who  
21 do this know how to take this. And they actually -- he's  
22 run all these chemicals through -- they're -- how to rank  
23 them in terms of their overall persistence, based not just  
24 on their persistence in one medium, but in the total  
25 environment. And that relates to how they make their way

1 around the environment. Like some things go into sediment  
2 and get buried and other things go into sediment and just  
3 sit there and slowly go into the water column. And as the  
4 concentration in the water column goes down, they go into  
5 the atmosphere and then get circulated.

6 So some get buried, some get circulated and you  
7 don't know that without really running it through these  
8 sorts of fate analyses. And then you could start seeing  
9 how these substances all compare to each other. And  
10 again, it's already been done. You know, I think you just  
11 call somebody who's been involved in persistent pollutants  
12 for 10, 15 years, and they'll say, oh, yeah, here's the  
13 paper. We ranked them all in terms of their global  
14 persistence and their likelihood they'll end up in the  
15 food chain, and their likelihood they end up in human  
16 lipids.

17 ACTING CHAIR PADULA: Any further questions?

18 STEPHANIE JARMUL: Just a reminder that they can  
19 ask questions on the Program update as well, in case there  
20 are any.

21 ACTING CHAIR PADULA: Right.

22 STEPHANIE JARMUL: Nerissa is very happy I said  
23 that.

24 (Laughter).

25 PANEL MEMBER DURRANI: Hi. Timur Durrani. This

1 is I guess for both of you. I've heard three different  
2 labs now, it's sounds like, Environmental Health Lab,  
3 Environmental Chemistry, and DTSC. And Nerissa, it  
4 sounded like part of the support role is to develop, come  
5 up with a lab's development and so forth. So can you talk  
6 a little bit about how that goes about and how you choose  
7 which lab, and which analytes go where, and that kind of  
8 thing?

9 DR. NERISSA WU: Sure. There are two labs as  
10 part of the Biomonitoring Program. And one is the  
11 Environmental Health Lab at CDPH and they generally  
12 measure metals, and then the urinary nonpersistent  
13 chemicals, like PAHs and VOCs. And then our persistent  
14 organic pollutants and PFASs are measured by the  
15 Environmental Chemistry Lab. That's over at DTSC.

16 Now, one of the pressures on the Program is there  
17 are all these emerging chemicals and trying to keep up  
18 with methods or expand our PFASs methods -- or PFAS method  
19 to include more of these emerging PFASs, it is quite a  
20 challenge for the lab. It's a very long process to go  
21 through that method development. So sometimes what we'll  
22 do, as I mentioned Amina Salamova's lab, is we'll work  
23 with an academic or private lab that's working on a new  
24 method. We might see in one of our pilot studies what's  
25 coming up that we want to consider and then try to

1 incorporate that method into one of the labs. In the case  
2 of PFASs, it would be over at DTSC. But it's something we  
3 have to consider carefully, because the -- just the  
4 resources and time that go into method development are  
5 considerable.

6 I don't know. Maybe one of the lab folks is  
7 online wants to address that.

8 ACTING CHAIR PADULA: Go ahead, Lara.

9 PANEL MEMBER CUSHING: Yeah. I had kind of a  
10 related question, which is I was just wondering if this  
11 would be more Nerissa or maybe you'll be presenting on  
12 this at a future meeting about the IPPs, and like the --  
13 because I know there was -- there's one about PFAS, but  
14 also PAHs and VOCs. So I was just kind of curious where  
15 those are, and how they went or are going, and what may be  
16 planned?

17 DR. NERISSA WU: So the IPP, the Intra-Program  
18 Pilot, it's our method development. It's beyond  
19 laboratory methods. It's really just trials of different  
20 laboratory or field processes that we want to try out on  
21 sort of an internal group, before we use it in a general  
22 biomonitoring study. So for example, in the past we  
23 looked at QACs with -- also with an external lab to see if  
24 it was something that we would consider bringing into a  
25 biomonitoring study. The PAHs were -- it was an

1 expansion -- or I guess an improvement of the method.

2           And so, again a demonstration that the data were  
3 usable, that we saw detection levels that we would expect  
4 to see. And it's an opportunity for us to kind of do a  
5 dress rehearsal and try out the method and make sure that  
6 the data is usable or useful before we promise it to  
7 external partners.

8           The last one, so PAHs we did run, and we're  
9 actually about to return those results to the  
10 participants. And I guess we -- we're -- as part of our  
11 consideration of 2026 topics, I mean, this might be  
12 something that comes up, we could talk about them as a  
13 body of work or we could have a discussion about why we  
14 chose to test a new method and what -- kind of what the  
15 outcome of that is. And this is particularly true for  
16 something like the microsampling devices, which I think  
17 everyone is really interested in hearing about. We'll be  
18 doing an assessment of both, you know, are we -- are there  
19 differences in capillary blood versus venal samples, how  
20 do the PFAS and metals results look between those two  
21 sampling techniques, but also what's the acceptability  
22 among participants? Do they -- do they like having  
23 samples collected in that way? Are they more or less  
24 painful than venipuncture?

25           So there -- I think there will be a lot of

1 results that come out of the next round of IPP that we'd  
2 be happy to share with you. But I think that would be a  
3 good addition to our discussion in 20 -- for the 2026  
4 topics about the things we would like to see.

5 DR. KATHLEEN ATTFIELD: And it's a small point.  
6 I'm Kathleen Attfield, a Research Scientist Supervisor  
7 over at EHIB. Just to point out, of course, that these  
8 IPPs are always small. It's like less than 40 people, so  
9 we don't try to use that data as sort of understanding  
10 anything about the California population per se. It's  
11 more about method development, and testing, and field  
12 implementation testing.

13 ACTING CHAIR PADULA: Okay. If there are no  
14 other questions, I want to just thank Nerissa and Ian  
15 again for a great presentation, and we will take a  
16 10-minute break and return at 2:20. Thanks so much.

17 DR. IAN TANG: Thank you all for your comments.

18 (Off record: 2:10 p.m.)

19 (Thereupon a recess was taken.)

20 (On record: 2:20 p.m.)

21 ACTING CHAIR PADULA: In the next agenda item, we  
22 will be hearing from several collaborators on the  
23 FRESSCA-Mujeres project. Ileana Navarro, Policy Associate  
24 at the Central California Environmental Justice Network;  
25 Dr. Mohammad Heidarinejad, an Assistant Professor in the

1 Department of Civil, Architectural, and Environmental  
2 Engineering at the Illinois Institute of Technology, and  
3 Stephanie Jarmul, Chief of the Safer Alternatives  
4 Assessment and Biomonitoring Section at OEHHA.

5 So today, they will give a joint presentation on  
6 the results and impacts of the FRESSCA-Mujeres study.

7 (Slide presentation).

8 STEPHANIE JARMUL: Thank you, Amy. I'll just  
9 briefly give an overview. Is this going to work?

10 [SLIDE CHANGE]

11 STEPHANIE JARMUL: There we go. So Ileana is  
12 going to be giving a study background. Ileana is  
13 attending online, so there she is. And then Mohammad will  
14 be providing an intervention analysis for the PM data. I  
15 will be giving the biomonitoring results, and then I'll  
16 pass it back over to Ileana who will discuss the FRESSCA  
17 community impacts and perspectives, and some next steps  
18 for the project. And with that, I'll turn it over to  
19 Ileana.

20 [SLIDE CHANGE]

21 ILEANA NAVARRO: Hi, everyone. My name is Ileana  
22 with the Central California Environmental Justice Network,  
23 or CCEJN, as Stephanie mentioned. Thank you so much for  
24 having me today. I'm super excited to share about the  
25 study and share those community impacts that we feel were

1 very impactful.

2 To start off, agricultural workers in  
3 California's San Joaquin Valley, they face this critical  
4 health challenge of spending super long hours working  
5 outdoors and then having to return to home without the  
6 proper air filtration. And this has left them  
7 disproportionately exposed to wildfire smoke.

8 And these exposures include wildfires, but also  
9 dust and smoke from agricultural fields and emissions from  
10 oil and gas operations. And I have here some photos taken  
11 from community members of their -- of their exposures.  
12 Many low-income families here also rely on evaporative  
13 coolers, or swamp coolers, which are the more affordable  
14 alternatives to air conditioners. And these systems they  
15 pull in massive amounts of unfiltered outdoor air, and  
16 then when the wildfires smoke -- when there's wildfires,  
17 the smoke, with the extreme heat, hit simultaneously and  
18 these homes become super hazardous. And this is what led  
19 us to launching the FRESSCA-Mujeres and FRESSCA Project.

20 Next slide.

21 [SLIDE CHANGE]

22 ILEANA NAVARRO: I'm going to be sharing with you  
23 all some videos from the community members that had the  
24 opportunity to record their experience through a community  
25 workshop led by Story Center. And this here is Erika's



1 story.

2 (Thereupon a video was played.)

3 ILEANA NAVARRO: We're going to pause it really  
4 quick right here just to continue talking more about the  
5 study, but we'll come back to this video at the end.

6 Next slide.

7 [SLIDE CHANGE]

8 ILEANA NAVARRO: The goal of FRESSCA -- of the  
9 FRESSCA Project was to address this need by developing an  
10 affordable filtration intervention for homes with swamp  
11 coolers. We also then built on this project and launched  
12 FRESSCA-Mujeres, which aimed to evaluate the effectiveness  
13 of the air filtration interventions at reducing in-home  
14 exposures and learn more about female agriculture workers'  
15 exposures to air pollution specifically in the Valley.  
16 And we recruited from Fresno, Kings, and Kern counties.

17 [SLIDE CHANGE]

18 ILEANA NAVARRO: This slide was presented by Jeff  
19 Wagner at last November's meeting, but just as a brief  
20 reminder, we have three funding sources and many  
21 interdisciplinary partners on the full study team, which  
22 included folks from -- folks involved in FRESSCA and  
23 FRESSCA-Mujeres.

24 [SLIDE CHANGE]

25 ILEANA NAVARRO: And then before Mohammad and

1 Stephanie go into details about the results, we wanted to  
2 provide a brief overview of the study components. The  
3 FRESSCA Pilot Project was conducted in 2022. And during  
4 that phase, we enrolled 25 homes from Kern and Fresno  
5 counties. We developed indoor and outdoor PM monitors and  
6 different types of filtration interventions in these  
7 homes, and participants also completed questionnaires.

8 Then in 2023, we launched FRESSCA-Mujeres. And  
9 then during this phase, we enrolled about 50 female  
10 agricultural workers from Kern, Kings, and Fresno  
11 counties. We installed portable air cleaners in all the  
12 homes and swamp cooler filters on half of the homes. It  
13 was designed this way, so that we can ensure that all  
14 participants had some sort of filtration in case of a  
15 wildfire event. And then to characterize exposures and  
16 evaluate the intervention, we measured air pollutant  
17 levels inside and outside of the homes, collected  
18 participant's urine to measure exposure biomarkers, and  
19 conducted questionnaires.

20 And now, I'll hand it over to Mohammad to provide  
21 details on the filtration intervention analysis.

22 Thank you.

23 [SLIDE CHANGE]

24 DR. MOHAMMAD HEIDARINEJAD: Thanks, Ileana.  
25 Thanks to Stephanie. My name is Mohammad Heidarinejad,

1 I'm an Associate Professor at Illinois Tech. I'm excited  
2 to be here to present on behalf of the FRESSCA team.

3 Looking into the FRESSCA, we had three different phases.

4 One phase was laboratory testing, pilot  
5 intervention, and the full intervention. The laboratory  
6 and the pilot was conducted in 2022. And the full  
7 intervention was in 2023. Before looking into the lab  
8 testing, I want to explain a little bit what the  
9 difference between the pilot year and the full  
10 intervention.

11 So we used the pilot year to learn more about the  
12 lessons learned that we deployed for the full  
13 intervention. So technically the number of homes  
14 increased significantly from the pilot year to the full  
15 intervention. They come -- the counties are almost  
16 identical. And in terms of the intervention, we usually  
17 deploy them in June, July and retrieve the interventions  
18 in October. And the goal was to make sure if there is a  
19 wildfire, we can capture the intervention for the air  
20 cleaning during that time.

21 One of the things we learned for the pilot year  
22 was if you look at the intervention types in the pilot  
23 year, we had so many different portable air cleaners. We  
24 decided to limit those numbers making sure all the  
25 portable air cleaners are HEPA filters. Also, we want to

1 make sure during the full intervention all the homes have  
2 means of air cleaning, meaning all the homes we call it  
3 single invention, at least had a portable air cleaner.  
4 And half of the other homes, they had double  
5 interventions, meaning in addition to their portable air  
6 cleaners, we were also like filtering the swamp coolers to  
7 make sure the outdoor air coming in is filtered.

8           One of the other things we learned during the  
9 pilot year, making sure that we can focus and  
10 understanding the usage of the portable air cleaners and  
11 the swamp coolers. So all the homes almost, if possible,  
12 during the full intervention, they had plug load logger,  
13 so they could see if they're operating the device, if  
14 they're operating at low, medium, or high speed.

15           The other thing we learned during the pilot year,  
16 making sure having some sort of memory in the monitors for  
17 indoor air quality and outdoor air quality could increase  
18 the capture rate.

19                           [SLIDE CHANGE]

20           DR. MOHAMMAD HEIDARINEJAD: So now, we want to  
21 look at a little bit before getting to the full  
22 intervention, the year, looking at the results. We want  
23 to learn about what is the focus we did in the laboratory  
24 to develop the filtration solution for the swamp coolers.

25           So the team made a visual survey of the homes and

1 they looked at the homes, their swamp coolers in terms of  
2 size, dimensions, and their location. Eighty-five them,  
3 we called them horizontal-flow, meaning they were going  
4 through the walls or the windows and they were not on the  
5 roof. And so we decided to focus on that because of the  
6 safety, also the predominance of horizontal swamp coolers.  
7 As you can see in the bottom, there are four figures. The  
8 three on the left-hand side show these are usually cubic,  
9 but also you have some sort of swamp coolers, they may  
10 have a little bit different basic dimensions, mostly two  
11 narrow side and then maybe one dominant side there. So we  
12 looked at different filter types. We'll talk about it  
13 more. And then ultimately we focused on these to make  
14 sure that --

15 [SLIDE CHANGE]

16 DR. MOHAMMAD HEIDARINEJAD: -- we can develop the  
17 solution for that.

18 In the laboratory, when we -- the team made this  
19 survey, they identified seven manufacturers for the swamp  
20 coolers in the area. We picked three of them that they  
21 were more common. And we acquired them in the lab. As  
22 you can see in the image on the right-hand side, a few  
23 different ways of mounting the filters.

24 These swamp coolers were tested. Even in the  
25 bottom right-hand side, you can see that we build the

1 enclosure of plenum type on it. We decided to abandon  
2 that, because it takes a lot of time to -- to do that.  
3 The overarching goals for this laboratory testing and the  
4 making sure the filtration for the swamp cooler was making  
5 sure the media could withstand the wet surfaces, because  
6 these swamp coolers have wet surfaces, making sure that  
7 it's not restrictive in terms of the flow. So we kind of  
8 have a 20 percent limit in terms of the flow that would be  
9 reduced.

10           Also, it should be cost effective and the owners  
11 should be able to acquire the pieces needed to put it  
12 together, so meaning limited training or no training is  
13 needed for that. Also, we want to make sure this solution  
14 is not permanent. It's only during the wildfire season.  
15 So as you can see in the results, which are these are good  
16 for a few weeks.

17                               [SLIDE CHANGE]

18           DR. MOHAMMAD HEIDARINEJAD: With that, we did the  
19 testing. So if you're looking at the figure here, we have  
20 two figures. The left-hand side shows two type of the  
21 coolers. They have centrifugal fans and the right-hand  
22 side has the axial fan. The vertical axis shows the flow  
23 rate. So if you look at the number, usually multiplied by  
24 0.6, you get it in CFM. So if you are looking at it,  
25 maximum gets to about 3,000 CFM. The horizontal axis

1 shows the pressure drop in these coolers.

2 So we did testing blocking different side of the  
3 cooler, as you can see the dashed line here. So you get  
4 system -- should I repeat it from the beginning?

5 (Laughter).

6 DR. MOHAMMAD HEIDARINEJAD: So one thing we  
7 realized here, if you're looking at it, so like the dashed  
8 lined shows when we did the testing of blocking different  
9 side of the cooler, and we get the system curve for that.  
10 The goal was to make sure it's only 20 percent restricted  
11 in terms of the flow rate. So if you are looking at the  
12 line here for the bottom basically line, that's the  
13 cutoff, in terms of the pressure drop. And this one is  
14 for the upper line. You are looking at a few different  
15 combination of filters being deployed here. So we looked  
16 MERV 13, MERV 11, even like some sort of thin shapes being  
17 used in terms of the filtration. Also, different because  
18 of the filters are tested. Almost all the filters you see  
19 on the left-hand side of this, they meet the criteria  
20 here.

21 For the axial fan, that like shape, it has like  
22 two narrow sides. Unfortunately, a lot of the filter  
23 solutions didn't work, but we ended up finding some sort  
24 of innovative way in the field to deploy filters for those  
25 coolers.

1 [SLIDE CHANGE]

2 DR. MOHAMMAD HEIDARINEJAD: Now, looking in terms  
3 of the filtration efficiency, basically removal efficiency  
4 of these filters. If we are looking at -- let's say we  
5 just focus on the left-hand side looking at this arrow,  
6 like meaning if no filter is being used for these swamp  
7 coolers, these pads are usually good for more than 5  
8 micrometers. But less than that, when we usually have the  
9 widest part, they are not good so meaning it -- we need to  
10 have some sort of filtration for the swamp coolers. And  
11 usually, we know these wildfires, it's important to focus  
12 on 0.3 to 0.5 micrometer. So as you could see here, about  
13 like, you know, 50, 60 percent or more than that removal  
14 efficiency could be achieved with this filter.

15 Similar patterns could be seen for like different  
16 cooler types. The left-hand side, these are the  
17 laboratory, you know, filters. We selected these in  
18 coordination and with the manufacturers, also, talking to  
19 the advisory group. The right-hand side shows the filters  
20 that they were locally available and they were tested.  
21 There are a little bit more that if we have time, we can  
22 come back and explain some of those.

23 [SLIDE CHANGE]

24 DR. MOHAMMAD HEIDARINEJAD: So now, we have the  
25 solution for the filtration for the swamp coolers. So



1 getting to the pilot and full intervention year. So we  
2 installed PurpleAir to monitor indoor in all the homes in  
3 terms of their air quality and eight nearby outdoor  
4 stations. Also to make sure that we can make  
5 determination, we co-locate these PurpleAirs for  
6 calibration. So we calibrate them with respect to others.  
7 And we ended up getting the calibration factors for each  
8 of these monitors.

9 [SLIDE CHANGE]

10 DR. MOHAMMAD HEIDARINEJAD: One of the things I  
11 mentioned in the pilot year, we learned if you solely rely  
12 on the WiFi, the capture rate may not be sufficient. So  
13 if you're looking at the figure here, these are 46  
14 monitors and the vertical axis here shows the capture  
15 rate. These are different homes and different monitors  
16 that we had. We still had a few with the WiFi on the  
17 left-hand side, but most of them they had on-site storage.  
18 So as you could see, the capture rate increased  
19 significantly when you have the on-site memory. In case  
20 the WiFi get disconnected, you still have the on-site  
21 storage to collect the data. That was one of the lessons  
22 learned that we used for the full intervention.

23 [SLIDE CHANGE]

24 DR. MOHAMMAD HEIDARINEJAD: Now, let's look at  
25 more detail in terms of the field intervention. We call

1 it single intervention, meaning all the homes they had a  
2 portable HEPA air cleaner. So if there's a wildfire, at  
3 least they could use these portable air cleaners. And for  
4 the other half of the homes, we call it double  
5 intervention, meaning both the portable air cleaner and  
6 the swamp cooler is also filtered air. So like any  
7 outdoor air come into this space, it's being filtered  
8 through these swamp coolers. So we'll see the results of  
9 that in the next few slides there. So we call this one  
10 double intervention versus single intervention.

11 Before looking at some time series data, let's  
12 look at some spot measurements. So one of the goals was  
13 to make sure it's not restricted in terms of the flow  
14 rate. So we kind of have the 20 percent limit there. So  
15 looking in July when the filters were deployed versus  
16 October, we call it new versus used. So as you could see  
17 over time, when the filters were removed or retrieved, so  
18 the flow rate reduction increased more from 13 to 17  
19 percent, we are still within the 20 percent range that we  
20 have. So indicating that the solutions that were deployed  
21 they meet the criteria that we have for the design.

22 [SLIDE CHANGE]

23 DR. MOHAMMAD HEIDARINEJAD: Now, the next step is  
24 before again looking at time series, let's look at another  
25 spot measurements. Important part is the particulate

1 removal efficiency, meaning how effective these filters  
2 and the solutions are, so looking at new versus used,  
3 meaning July versus October when the filters were  
4 retrieved. So as you could see for different  
5 size-resolved bins, from 0.3 to 1 micrometer. So over  
6 time, the particulate removal efficiency dropped from 49  
7 percent to 36 percent. And as expected for like the  
8 filters, as you go up, the filtration efficiency goes up,  
9 but also again decrease over time significantly,  
10 indicating that the solution is good, but only works for a  
11 few weeks possibly.

12 Now, we want to look at if really these double  
13 intervention solution work. So you'll see a box plot  
14 here. We call it constrained PM indoor and outdoor ratio,  
15 the vertical axis. So it goes from 0 to 1. And the  
16 horizontal axis shows two groups. The first group here is  
17 the double intervention, meaning homes with PAC, portable  
18 air cleaners, and the EC filter. The right-hand side  
19 shows only single intervention, meaning the portable air  
20 cleaners being used.

21 So one of the things you are seeing here, the  
22 median for the I/O ratio is slightly increased when the  
23 ECs become on, like these dark blue from 57 to 63 percent,  
24 meaning that slightly the outdoor origin particulate  
25 matters are coming to the space, but the filters are still

1 able to filter most of that. But when we are looking at  
2 the homes with only PAC filtration, that number increased  
3 significantly from 55 percent to 78 percent, meaning that  
4 those outdoor air coming from the coolers, they are not  
5 filtered, and the portable air cleaner is not able to  
6 catch up with that. So indicating the double intervention  
7 is what we are looking at it for here as a promising  
8 solution.

9 [SLIDE CHANGE]

10 DR. MOHAMMAD HEIDARINEJAD: Looking at the same  
11 thing we saw before, like, you know, new versus used, like  
12 the first three weeks and also the last three weeks of the  
13 deployment. So you see the same thing here, the I/O ratio  
14 for the first three weeks versus the last three weeks. So  
15 the first three weeks, we are not seeing noticeable  
16 changeover in terms of I/O when the filters are deployed.

17 But over time, as you could see, that I/O ratio  
18 increased from 55 to 69 percent, meaning the filters are  
19 not able to catch up over time a little bit more than what  
20 you see at the beginning. There are several reasons for  
21 that, but it's again indicating the solution is temporary,  
22 but could work well during the wildfire season.

23 [SLIDE CHANGE]

24 DR. MOHAMMAD HEIDARINEJAD: Now, before like  
25 getting to the summary, let's look at two times. One we

1 call it non-wildfire period, meaning like most of the  
2 times that these filters were deployed in that three, four  
3 months. And as you could see here, again the same thing  
4 on the I/O ratio, like for double intervention, slight  
5 increase, not significant, similar result happening here  
6 for the PAC only, like over you'll see like more outdoor  
7 air origin like PM2.5 are coming in, and the PACs are not  
8 able to catch up with that.

9 [SLIDE CHANGE]

10 DR. MOHAMMAD HEIDARINEJAD: We can look at during  
11 the wildfire season, we had two times in August and also  
12 in September. You could see the impact is a similar  
13 pattern, but it's a little bit more severe here. So for  
14 like single interventions, like meaning the homes again  
15 with no filtration on their swamp coolers, that number  
16 increased more than what we saw during the non-wildfire  
17 times.

18 One thing to emphasize here, during the study  
19 year, we had wildfire, but it was not as severe as  
20 previous years. But again, looking at the results here  
21 confirm this solution works well.

22 [SLIDE CHANGE]

23 DR. MOHAMMAD HEIDARINEJAD: In summary, we looked  
24 at these air filtration solutions for both the pilot and  
25 intervention year, and the solution with the filtering the

1 swamp coolers. We call it DIY, do it yourself, meaning  
2 the homeowners with no training can do that. We also  
3 looked at materials and filters that could be mostly  
4 accessible and available to be installed.

5 One thing, we had it earlier, didn't get a chance  
6 to get into that in more detail, we used MERV 13. It's  
7 recommended for the filters. It also followed the same  
8 recommendation that EPA and ASHRAE has. Also having  
9 portable air cleaners with HEPA filters are effective in  
10 terms of lowering the PM2.5 and PM10 levels in homes.

11 And ultimately, the solution is it could be good  
12 for a few weeks, but their efficiency and effectiveness  
13 will decrease over time. So overall, it's important to  
14 make sure these swamp coolers, when they are drawing a  
15 significant amount of outdoor air, are filtered during the  
16 wildfire season.

17 Before passing it to Stephanie, I want to thank  
18 the colleagues who worked on this. We have a few of them  
19 here in person and few online and happy to respond to any  
20 questions after the presentation.

21 Stephanie, I'll pass it to you.

22 [SLIDE CHANGE]

23 STEPHANIE JARMUL: Thanks so much, Mohammad. And  
24 also big shout-out to the larger FRESSCA team and also the  
25 team at SAABS for doing a lot of these analyses that I'll

1 be presenting on today for the biomonitoring data.

2 So other than the PM data, we also measured  
3 levels of PAHs, VOCs, and metals in indoor and outdoor  
4 air. Those results were presented at a previous SGP  
5 meeting by Jeff Wagner last November. So today, we'll be  
6 discussing the PAH, VOC, and metals data in the urine  
7 samples. The FRESSCA-Mujeres study also did measure  
8 biomarkers of stress in urine, and included saliva  
9 telomere length and silicone wristbands to measure  
10 pesticides for a small subset of participants, but we will  
11 not be covering those data today.

12 [SLIDE CHANGE]

13 STEPHANIE JARMUL: So here's a look at our  
14 demographics. We had 51 participants who provided at  
15 least one urine sample. They were all non-smoking,  
16 Hispanic/Latina women who primarily spoke Spanish. The  
17 mean age was 41, and a majority owned their home, and had  
18 Medi-Cal or Medicare, and most participants were either  
19 farmworkers or worked in some sort of food packaging and  
20 processing facility.

21 [SLIDE CHANGE]

22 STEPHANIE JARMUL: So we put together this  
23 timeline to try to help clarify what data were collected  
24 and when, since there's so many moving parts. And as we'd  
25 stated, the study was designed to try to capture exposures

1 during a wildfire event. So what -- we collected a first  
2 morning void sample in the spring/summer months to  
3 establish sort of baseline exposures. Surveys were also  
4 conducted at that time.

5 At the same time, we installed PurpleAir monitors  
6 to monitor for PM and passive air samplers for PM and  
7 metals at the homes of the participants. And then we  
8 installed the portable air cleaners in all the homes and  
9 the swamp cooler filters in half the homes, in hopes to  
10 prepare for a wildfire event. As we did not have any  
11 major event, we waited until October to collect the urine  
12 samples. We collected one in the evening and then another  
13 a first morning void. This design was chosen to see if  
14 there might be any potential differences in the  
15 metabolites of PAHs and VOCs, after spending time in the  
16 filtered air. And that's because the PAHs and VOC  
17 half-lives are short, generally within six to eight hours.

18 And then active air sampling was conducted for  
19 the 24-hour period preceding the collection of the fall  
20 morning samples. And we collected VOCs, PAHs, and metals  
21 data for that.

22 [SLIDE CHANGE]

23 STEPHANIE JARMUL: So getting into the data  
24 analysis. Non-detects were imputed with reporting limit  
25 over the square root of two and we did not conduct any



1 analyses, if we had detection frequencies less than 65  
2 percent. The urine results were adjusted for specific  
3 gravity to account for dilution and adjust -- and were log  
4 transformed. However, we did use creatinine-adjusted  
5 values for our comparisons with NHANES.

6 The number of samples may change depending on the  
7 analysis, as not all participants provided all three urine  
8 samples. And then for any of our geospatial analyses that  
9 we're including today, we were provided with approximate  
10 participant locations to not include any PID.

11 [SLIDE CHANGE]

12 STEPHANIE JARMUL: So here are the detection  
13 frequencies we had in the chemicals measured in urine.  
14 And you can see we had pretty high detection frequencies  
15 for almost all the chemicals, though 1,3-butadiene,  
16 benzene, and manganese all had low detection frequencies,  
17 and therefore they'll not be included in the analyses on  
18 the following slides.

19 [SLIDE CHANGE]

20 STEPHANIE JARMUL: So one of the questions we had  
21 was we wanted to see if the levels of PAH and VOC  
22 metabolites decreased after spending time in filtered air.  
23 We did not look at metals for this question as our  
24 half-lives were much longer. And we would not expect to  
25 see a difference in such a short amount of time. We also

1 checked if we could see any difference in metabolite  
2 levels based on intervention types, similar to the  
3 question that Mohammad wanted to answer using the PM data.

4 [SLIDE CHANGE]

5 STEPHANIE JARMUL: So participants, as I  
6 mentioned, provided urine samples in the evening,  
7 generally when they got home from work, and then again  
8 about 12 hours later after sleeping at home in the morning  
9 sample. And so what this plot shows is the estimated  
10 percent change in concentration between a participant's  
11 fall evening and fall morning urine sample. The color  
12 blue here - this may be a little hard to see - means the  
13 difference was significant. And so you can see that  
14 metabolites of fluorene, phenanthrene, and pyrene were  
15 either about the same or lower during this time period,  
16 while metabolites of naphthalene increased, particularly  
17 2-NAP. And this might point to perhaps an indoor exposure  
18 source of naphthalene that we'll get into a little bit  
19 later.

20 [SLIDE CHANGE]

21 STEPHANIE JARMUL: And then looking at the VOC  
22 changes, again this plot shows the estimated percentage  
23 change in VOC metabolite concentrations overnight. And  
24 similar to the PAHs, you can see that metabolites of VOCs  
25 were about the same or lower during this time period, and

1 with acrolein being significant and about 20 percent lower  
2 in the morning samples than the evening samples.

3 [SLIDE CHANGE]

4 STEPHANIE JARMUL: So as I stated, metabolites of  
5 both PAHs and VOCs generally decreased after spending time  
6 indoors, except for naphthalene. This might partially be  
7 explained by air filtration, but it could also be due to  
8 differences in behaviors during work versus while they're  
9 at home.

10 We did look at differences in the spring versus  
11 fall samples based on paired t-tests of the morning  
12 samples. Since, as we mentioned, we were originally  
13 expecting much higher pollutant levels in the fall due to  
14 a wildfire event. However, as there was no major wildfire  
15 event, we did not see any significant differences between  
16 the fall and spring morning samples.

17 We also did not see a significant difference in  
18 metabolite levels based on the intervention type. And  
19 Jeff Wagner's team had a similar finding for the PAHs and  
20 VOCs in air. Again, since we didn't have a major wildfire  
21 event, I think it would be hard to see differences at that  
22 level of granularity in the biomarkers especially. And  
23 also our Ns reduced even further when we had to split them  
24 among the two intervention groups.

25 And additionally, it was found that a majority of

1 participants were not actually running their swamp coolers  
2 the night that we collected the urine samples and had the  
3 24-hour air sampling, which makes even more sense why we  
4 weren't able to see a difference.

5 [SLIDE CHANGE]

6 STEPHANIE JARMUL: Okay. So the next question we  
7 had was how do the levels of metals in PAH and VOC  
8 metabolites in FRESSCA-Mujeres compare to NHANES?

9 [SLIDE CHANGE]

10 STEPHANIE JARMUL: Starting with metals

11 [SLIDE CHANGE]

12 STEPHANIE JARMUL: So we used a geometric means  
13 of each participant's geometric mean across all three time  
14 periods to compare to NHANES. We saw similar results when  
15 we compared NHANES to each time period separately, which  
16 is why we felt comfortable with this approach. You can  
17 see here that the geometric means of antimony, arsenic,  
18 and cadmium were similar or lower in FRESSCA compared to  
19 NHANES non-smoking women.

20 Mercury was higher, though not significant.  
21 Nickel was the only metal where we saw significantly  
22 higher levels than NHANES. However, we also had seven  
23 cases of mercury and/or arsenic levels above Biomonitoring  
24 California's Levels of Concern, which I'll be going into  
25 more details a bit later.

1 [SLIDE CHANGE]

2 STEPHANIE JARMUL: So for nickel, it was about  
3 1.5 times higher in FRESSCA compared to NHANES. We didn't  
4 find anything unfortunately that jumped out based on the  
5 questionnaire data. And we asked questions such as  
6 working with metals, either through their occupation or  
7 hobbies, and we didn't see any difference based on  
8 occupation. We also did not have any detects in the  
9 FRESSCA air sampling data that was for the 24 hours before  
10 sample collection. However, we did have a number of  
11 detects in the passive air samplers and also the EC  
12 filters. And those were up for a much longer period of  
13 time.

14 So the fact that we're seeing nickel in those  
15 samples might be more relevant due to the long half-life  
16 of nickel. This also indicates exposures might still be  
17 coming from air, since they were captured in those filters  
18 and the samplers and will be -- and nearby oil and gas  
19 activities might be a potential exposure source, which  
20 again we'll talk about a little bit later. And just to  
21 check, we did look at the drinking water data and did not  
22 find any detects of nickel in the drinking water data for  
23 these participants.

24 [SLIDE CHANGE]

25 STEPHANIE JARMUL: So as I discussed, we had five

1 participants who had mercury above Biomonitoring  
2 California's Level of Concern and they all received early  
3 notification. Three of those participants agreed to  
4 participate in an additional exposure survey. The image  
5 to the right here includes a number of products imported  
6 from other countries that CDPH has found to contain  
7 mercury. These are skin creams. Two of them were used by  
8 our participants and we connected these participants with  
9 a team at CDPH who was actually able to test the skin  
10 creams of the participants and found mercury in all the  
11 samples of their skin creams.

12 And CDPH also conducted home assessments for two  
13 of those participants and did not find any other exposure  
14 sources in the home, which confirmed that the skin creams  
15 are the most likely source of these high mercury levels in  
16 the participants.

17 [SLIDE CHANGE]

18 STEPHANIE JARMUL: And then we had three  
19 participants who had total arsenic above Biomonitoring  
20 California's Levels of Concern, and again received early  
21 notification from our team. One participant had high  
22 levels of organic arsenic, which is likely due to seafood  
23 consumption and then less of a concern. Two participants  
24 did though have elevated inorganic arsenic levels. One  
25 agreed to participate in an additional exposure survey.

1 Unfortunately, nothing really stood out based on the  
2 results of that survey, but we think we can at least rule  
3 out drinking water for this participant as they were using  
4 vended water for drinking and cooking, which removes  
5 arsenic. And we also did not find any high levels of  
6 arsenic in the drinking water data for this participant.

7 [SLIDE CHANGE]

8 STEPHANIE JARMUL: Okay. So next, we wanted to  
9 look at VOCs and any potential differences in the  
10 metabolites in FRESSCA compared to NHANES.

11 [SLIDE CHANGE]

12 STEPHANIE JARMUL: So metabolites of  
13 acrylonitrile and crotonaldehyde were similar or lower  
14 than NHANES, but acrolein and propylene oxide were  
15 significantly higher in our FRESSCA population than NHANES  
16 non-smoking women.

17 [SLIDE CHANGE]

18 STEPHANIE JARMUL: And so we wanted to look into  
19 what exposure sources might be contributing to the high  
20 levels of acrolein and propylene oxide metabolites in our  
21 participants. And while all samples, so spring and both  
22 fall and morning samples -- fall morning/evening samples  
23 were generally higher than NHANES, we still did see higher  
24 levels in the post-work evening samples for both acrolein  
25 and propylene oxide. So it's 27 percent higher in the

1 acrolein metabolites and 16 percent higher in the  
2 propylene oxide metabolites.

3 We also found for acrolein that the levels were  
4 17 percent higher for each additional hour worked outside.  
5 We think that this points to potentially exposure sources  
6 that are happening outside the home for these  
7 participants. And we did also find evidence that acrolein  
8 and propylene oxide were ingredients in pesticides that  
9 were applied in the region in 2023. And that was based on  
10 DPR data. And unfortunately, we did not have  
11 FRESSCA-Mujeres indoor or outdoor air monitoring data for  
12 acrolein or propylene oxide.

13 [SLIDE CHANGE]

14 STEPHANIE JARMUL: Okay. And as I alluded to,  
15 additionally for both acrolein and also nickel, we wanted  
16 to see if the high levels in our population might be  
17 explained by oil and gas activities in the Central Valley.  
18 Elevated levels of acrolein were found in the air in Lost  
19 Hills, a community within Kern County, which is one of our  
20 counties. And that's based on data from CARB's SNAPS  
21 report. Nickel is also often detected in air around oil  
22 and gas activities such as oil refineries. And you can  
23 see in this map that there are literally hundreds of oil  
24 and gas wells in these communities and a number of oil  
25 refineries as well.



1           We only had six participants however who lived  
2 within 3,200 feet of an active well. And we chose that  
3 buffer, because it is considered the health protection  
4 zone around oil and gas operations. And that's out of  
5 Senate Bill 1137, though we are planning on looking at  
6 some larger buffer zones in the future as well.

7           And even though only six participants lived  
8 within 3,200 feet of a well, we don't have the locations  
9 of participant work locations, which may be more relevant  
10 to their exposure period, since that would be where they  
11 would be exposed to unfiltered outdoor air. And, yes, we  
12 do not have those locations unfortunately.

13                           [SLIDE CHANGE]

14           STEPHANIE JARMUL: Okay. Switching to PAH  
15 metabolites in urine.

16                           [SLIDE CHANGE]

17           STEPHANIE JARMUL: So again, we compared the  
18 geometric means of participants in FRESSCA to NHANES, and  
19 found that the PAH metabolites were all lower in  
20 FRESSCA-Mujeres women, which was good news, except for  
21 2-naphthol. So you might recall hearing a lot about  
22 2-naphthol from our SAPEP and BiomSPHERE studies, where it  
23 was also elevated.

24                           [SLIDE CHANGE]

25           STEPHANIE JARMUL: So you can see in this graph

1 here, we compared the levels from FRESSCA-Mujeres, which  
2 were all non-smoking Hispanic women to a subset of women  
3 from our BiomSPHERE study, which were also Hispanic women.  
4 And then we wanted to look specifically at the Hispanic  
5 women in NHANES since, from some of our previous analyses,  
6 we know that it is generally higher than the average  
7 levels in NHANES adults, either women or adults, both male  
8 and female.

9 And you can see here that the FRESSCA Hispanic  
10 women had similar levels of 2-NAP compared to Hispanic  
11 women in BiomSPHERE. And then the levels of 2-NAP in both  
12 FRESSCA and BiomSPHERE Hispanic women were still 2.5 times  
13 higher than Hispanic women in NHANES and four times higher  
14 than women in NHANES.

15 Just want to note here, you can see that the most  
16 recent data we're still working with in NHANES is from  
17 2015 to 2016, which is almost a decade ago.

18 [SLIDE CHANGE]

19 STEPHANIE JARMUL: And we also saw something  
20 similar in our BiomSPHERE study with these correlations.  
21 And you can see that the PAHs were all significantly  
22 correlated with each other, including 1-NAP, except for  
23 2-naphthol. The difference is pretty stark here, so we  
24 think there's definitely a unique exposure to 2-NAP that  
25 is not relevant to the other PAHs.

1 [SLIDE CHANGE]

2 STEPHANIE JARMUL: So we showed earlier on in our  
3 slides that the 2-NAP levels were 16 percent higher in the  
4 morning samples versus the evening samples, again pointing  
5 potentially to an indoor exposure source. We did not find  
6 any significant associations with cleaning product or air  
7 freshener use, which is different from what we had found  
8 in BiomSPHERE. Unfortunately though, similarly to  
9 BiomSPHERE, we did not find any significant associations  
10 with diet, such as consumption or cooking in fried or  
11 smoked foods. But we might be missing some other  
12 associations with dietary sources that we did not capture  
13 in our questionnaire.

14 Additionally, some recent data that we've come  
15 across in terms of speaking with other biomonitoring  
16 programs indicates that 2-NAP is generally increasing both  
17 in the country and actually globally, but nowhere near the  
18 levels that we are seeing in SAPEP, BiomSPHERE, and  
19 FRESSCA.

20 [SLIDE CHANGE]

21 STEPHANIE JARMUL: So again, still trying to  
22 piece together the puzzle that is 2-NAP in our  
23 populations. But with that, I will turn it back over to  
24 Ileana who will discuss the community impacts and  
25 perspectives of the FRESSCA-Mujeres study.

1 ILEANA NAVARRO: Thank you, Stephanie.

2 Can we go to the next slide, please.

3 [SLIDE CHANGE]

4 ILEANA NAVARRO: Thank you. So the community  
5 response to FRESSCA has been overwhelmingly positive and  
6 incredibly insightful. Participants expressed deep  
7 gratitude for the portable air cleaners, for the free  
8 maintenance to their swamp coolers that we provided. And  
9 they reported noticeable improvements in their indoor air  
10 quality and even in their health.

11 Although we didn't experience a major wildfire  
12 event during the study period, many participants told us  
13 that the interventions made a real difference during dust  
14 storms, which we get a lot. With the swamp cooler filters  
15 in place, participants felt far less dust penetrated their  
16 homes, making these events a little bit more manageable.

17 However, participants did note that the biggest  
18 challenge was the bulky filters and the difficulty to  
19 install them and remove them. Beyond air quality though,  
20 participants were genuinely shocked to learn about the  
21 mercury-containing skin creams. A few actually owned  
22 these products, as you heard, and were super grateful to  
23 understand the health risks that they -- that they were  
24 posing. Most importantly, participants felt empowered by  
25 being part of this research.

1           It was a bit hard to grasp the technical analysis  
2 in the results packets that they received at the end of  
3 the study, but most participants already knew that they  
4 were being affected someway or another. They just didn't  
5 understand at what levels. And this study brought them  
6 that sense of credibility to their stories they've been  
7 telling for years, but no one has really taken seriously.

8           And at the end, they really just wanted to know  
9 that their participation would lead to better and more  
10 accessible filtration options for the agricultural  
11 communities in -- in the Valley.

12           Next slide.

13                           [SLIDE CHANGE]

14           ILEANA NAVARRO: And as mentioned at the  
15 beginning, I'm going to play the rest of Erika's video  
16 where she talks more about the FRESSCA -- how the FRESSCA  
17 study impacted her.

18           (Thereupon a video was played.)

19           ILEANA NAVARRO: Next slide, please.

20                           [SLIDE CHANGE]

21           ILEANA NAVARRO: Lastly, I'm just going to talk  
22 about the next steps for the FRESSCA-Mujeres project. We  
23 are planning to promote ways to reduce exposures in the  
24 FRESSCA-Mujeres communities and beyond through portable  
25 air -- portable air cleaners in homes, swamp cooler

1 filters during a wildfire event, and conducting some  
2 community engagement to reduce those exposures to mercury  
3 skin creams that we found and to arsenic. We also want to  
4 continue research to identify potential exposure sources  
5 of naphthalene and other chemicals of interest. Through  
6 this -- we want -- to do this, we want to combine data  
7 from the FRESSCA-Mujeres, BiomSPHERE, and the SAPEP to  
8 identify trends and also assess geospatial predictors of  
9 traffic exposures.

10 And with that, that is the end of my portion of  
11 the presentation. I'll pass it back to Stephanie.

12 Thank you all.

13 STEPHANIE JARMUL: Thank you so much, Ileana.

14 [SLIDE CHANGE]

15 STEPHANIE JARMUL: And here, we have our very  
16 large study team for the FRESSCA study, with whom we could  
17 not have done any of this work. So thanks. And some of  
18 them are here today, so it's nice to see them.

19 [SLIDE CHANGE]

20 STEPHANIE JARMUL:

21 And, of course, thank you to our community  
22 members who participated in this project, the scientific  
23 advisors and the Community Advisory Group. And here's the  
24 funding statement.

25 [SLIDE CHANGE]

1           STEPHANIE JARMUL: And with that, we'll take any  
2 questions for any of the three of us.

3           ACTING CHAIR PADULA: Thank you, team, for a  
4 great presentation. Any -- starting off with clarifying  
5 questions from the Panel.

6           Go ahead, Tom.

7           PANEL MEMBER MCKONE: Tom McKone. I'm really and  
8 also kind of fascinated by the 2-naphthol and why that  
9 differed. And so you looked at diet, but I was wondering  
10 if you looked at how food is prepared differently in  
11 California, like -- or even such a thing as our natural  
12 gas. I assume they're using gas. There's a different  
13 composition than the average we would see in NHANES. And  
14 then thoughts I had about what might account for the  
15 different indoor level of naphthalene.

16          STEPHANIE JARMUL: That is an interesting  
17 thought, because I'm pretty sure all of the FRESSCA  
18 participants used gas appliances and had a gas stove. So  
19 I don't -- yeah, we never really looked into if there  
20 could be different compositions of the gas in California  
21 or particularly in the Central Valley. So that's some  
22 associations we can run. I think we're mostly looking at  
23 VOCs for those associations. But, yeah, we should look  
24 into naphthalene specifically. Thank you.

25          ACTING CHAIR PADULA: Carl.

1 PANEL MEMBER CRANOR: It's a simple question, but  
2 did you have a measure of toxicity in selecting the  
3 substances you studied or did you just take what was  
4 present?

5 STEPHANIE JARMUL: Sorry. Do you mean how did we  
6 choose the metabolites to measure?

7 PANEL MEMBER CRANOR: Yes.

8 STEPHANIE JARMUL: Well, we had chosen PAHs,  
9 VOCs, and metals, because, as we mentioned, the goal of  
10 the study was to capture a wildfire event and we were  
11 aware that these are generally apparent in wildfire smoke.  
12 And the exact metabolites we're able to run, it was a bit  
13 limited by what our labs were able to run. And, of  
14 course, it to be on the designated list, but there was  
15 evidence that all the ones that we chose are often present  
16 in wildfire smoke.

17 PANEL MEMBER DURRANI: Timur Durrani. I thought  
18 you mentioned that you guys had also measured biomarkers  
19 of stress in urine. Can you talk a little bit about that?

20 STEPHANIE JARMUL: Yeah. So for our other  
21 studies, we measured only three or four biomarkers of  
22 stress through Nina Holland's lab. And for the FRESSCA  
23 study, this is -- this is not really Biomonitoring  
24 California's part of the study, but as the FRESSCA-Mujeres  
25 study, they measured 19 different biomarkers of stress



1 from a lab out of New York. And so we do have plans to  
2 look a little bit more closely at that data and see if we  
3 can see any associations between the biomarkers of  
4 exposure and effect. But we're not as clear how to handle  
5 all those 19, so it might take us a little bit longer to  
6 try to make sense of all the data.

7 ACTING CHAIR PADULA: Go ahead, Jenny.

8 PANEL MEMBER QUINTANA: I'm sorry if you touched  
9 on this, but could agricultural burning contribute to the  
10 naphthalene exposures or metabolites? I wasn't sure if  
11 that was an area that had a large contribution, but I  
12 think -- I know many -- much of the Central Valley does  
13 have a fairly large contribution.

14 Thank you.

15 STEPHANIE JARMUL: I think it could. Although,  
16 we aren't seeing very high levels in air for naphthalene.  
17 You know, it's always the most abundantly detected PAH,  
18 but at levels that we see in other areas too where we  
19 don't see the same high levels of 2-NAP in the urine.

20 PANEL MEMBER QUINTANA: Thank you.

21 PANEL MEMBER SUÁREZ: How about the prevalence of  
22 the use of mothballs in this population?

23 STEPHANIE JARMUL: Unfortunately, we did not ask  
24 about mothballs. This is going on at the same time as our  
25 BiomSPHERE study, so before we really learned that we

1 should add that to a future study, which we are going to  
2 do for the CHAIRS study. We did not ask specifically  
3 about mothball use. But for every single person to be  
4 using mothballs, it just seems unlikely. Although, it  
5 might still be possible.

6 PANEL MEMBER SUÁREZ: I mean, not every single --  
7 I mean, it -- was it substantially higher in every single  
8 person or are we just --

9 STEPHANIE JARMUL: I think --

10 PANEL MEMBER SUÁREZ: -- looking at the average  
11 here comparing --

12 STEPHANIE JARMUL: I think every single person  
13 had very high levels. Of course, there was a range. I  
14 don't know, Dan, if you have a little bit more details on  
15 that, but...

16 PANEL MEMBER SUÁREZ: That would be unusual.

17 DAN SULTANA: Yeah, it was generally higher  
18 for -- in the study.

19 STEPHANIE JARMUL: Oh, that's right. When we  
20 talked to the Minnesota Biomonitoring team about some  
21 higher levels that they were seeing, though not as high as  
22 hours, they had asked a question about mothballs. And I  
23 think they only found like a few people had been using  
24 them in their population.

25 PANEL MEMBER SUÁREZ: Right. I mean, I wonder if

1 their difference isn't in their population versus here.

2           STEPHANIE JARMUL: It's true there were -- yeah,  
3 they didn't have as many Hispanic people in their  
4 populations. And interestingly enough, they had found  
5 elevated levels in Black participants, which if you recall  
6 in BiomSPHERE, we had found a similar finding, although we  
7 only had a few Black participants in the study, so we  
8 couldn't really make any conclusions, but it's interesting  
9 that they're finding a similar trend.

10           And then there is a study that recently came out  
11 in the east coast, I think Maryland/D.C. area. It was a  
12 small study looking at occupational exposures to  
13 hairdressers, both Black and Latina women. And that's the  
14 only study we found that has come close to the levels that  
15 we're seeing in our population, which is very interesting,  
16 but our population was not obviously hairdressers, so --  
17 yeah, that's something else that we're looking over.

18           PANEL MEMBER DURRANI: Timur Durrani. Can you  
19 talk about the exposure survey that went on for -- I know  
20 you did it for mercury, but for arsenic. How did that go  
21 about or is that -- can someone review how did that occur  
22 once you see this level above a threshold.

23           STEPHANIE JARMUL: So I might pass it to McKenna,  
24 but -- so, when we are notified that the levels are above  
25 our Level of Concern, we essentially send them a packet

1 that is -- let's them know that the levels are above a  
2 concern and potential exposure sources and then we invite  
3 them to participate in another exposure survey that asks  
4 more detailed questions about potential exposure sources.  
5 So for arsenic, you know, we even asked about like teas,  
6 supplements, where they got their drinking water source  
7 from, things like that. And for that one participant who  
8 conducted the additional survey, we were not able to find  
9 anything significant that stood out. We asked even about  
10 like specific brands that we looked into and couldn't find  
11 anything.

12 MCKENNA THOMPSON: I think you covered it.

13 (Laughter).

14 ACTING CHAIR PADULA: We can also open it up to a  
15 general discussion, if we haven't already.

16 PANEL MEMBER SUÁREZ: I have more questions. And  
17 part of it is the same thing trying to understand what you  
18 make of it. So looking at that same table here comparing  
19 the VOCs. And this is José Suárez, by the way. Sorry.

20 Naphthalene, right, is higher, but then the other  
21 part is substantially lower for pretty much everything  
22 else. What are your thoughts on that?

23 STEPHANIE JARMUL: You mean, for the PAHs in  
24 general, why they're lower?

25 PANEL MEMBER SUÁREZ: Well, the ones that are at

1 least shown here, right?

2           STEPHANIE JARMUL: Yeah. That is a very  
3 interesting question. I'm not really sure why they are so  
4 much lower? You know, they're significantly lower in our  
5 population, which, you know, we take as good news, but I  
6 can't really say why.

7           PANEL MEMBER SUÁREZ: Yeah. I mean, it's  
8 something that once you're getting to that part of it,  
9 writing and doing the discussion, it is also a very  
10 interesting finding, what is it about these populations  
11 that are leading with that, but it sounds like somebody  
12 maybe has a thought.

13           McKENNA THOMPSON: I was just going to point out,  
14 I believe our -- this is McKenna Thompson from OEHHA.

15           (Laughter).

16           McKENNA THOMPSON: I believe our collaborators at  
17 UC Berkeley have found that PAHs in air in the Central  
18 Valley in general have been going down over the past 10  
19 years, so that could be a contributing factor.

20           STEPHANIE JARMUL: And is that due to like  
21 different regulations?

22           McKENNA THOMPSON: (Nods head).

23           STEPHANIE JARMUL: Yeah.

24           DR. JOHN BALMES: Yes.

25           STEPHANIE JARMUL: Okay. Great.

1 (Laughter).

2 That was John Balmes in the affirmative.

3 DR. JOHN BALMES: Less diesel emissions and less  
4 agricultural burning.

5 STEPHANIE JARMUL: Okay. John Balmes said less  
6 diesel emissions and less agricultural burning. Okay.

7 PANEL MEMBER SUÁREZ: Would it be enough to  
8 explain this lower concentration versus NHANES for that  
9 matter? Are the -- is the pollution substantially lower  
10 as a result of that in the Valley than the average U.S.  
11 area?

12 DR. JOHN BALMES: No, actually -- this is John  
13 Balmes again. Actually, the levels are higher in --  
14 they've gone down substantially, but they're higher than  
15 many parts of the country. I mean, the Fresno area and  
16 actually at the Bakersfield area, those are two of the  
17 most polluted cities in the country --

18 PANEL MEMBER SUÁREZ: Yeah, that was --

19 DR. BALMES: -- from traffic related air  
20 pollution.

21 PANEL MEMBER SUÁREZ: That was my understanding  
22 too, but I was coming back to this, right.

23 STEPHANIE JARMUL: Great point. Great question  
24 that we'll look into further.

25 PANEL MEMBER SUÁREZ: I can --

1           ACTING CHAIR PADULA:   You have a question.

2           PANEL MEMBER SUÁREZ:   I have more questions, but  
3 I'll --

4           SUSAN HURLEY:   After him.

5           PANEL MEMBER SUÁREZ:   Oh, no.   Please, please go  
6 ahead.

7           SUSAN HURLEY:   Okay.   Well, it's kind of related  
8 to that just that -- oh, Susan Hurley from CDPH,  
9 Biomonitoring.

10           Just following up on John's point.   While the  
11 levels of a lot of PAHs in the air may be going -- or may  
12 be higher in California.   The other thing to remember is  
13 we do have this temporal issue, where we're comparing our  
14 levels to data in NHANES that was collected 10 years ago.  
15 So we can't tell if this is a geographic issue or a  
16 temporal issue.

17           DR. BALMES:   That's a very good point.

18           STEPHANIE JARMUL:   Great point.   And even that  
19 for fluorene it was 2011 to 2012, so even longer than --  
20 and I don't know how hopeful we are that any new data  
21 might be coming out soon.

22           STEPHANIE JARMUL:   José.

23           (Laughter).

24           PANEL MEMBER SUÁREZ:   José Suárez.   So another  
25 big thing was compliance that you were concerned about.

1 Tell me a little bit more about -- do you have any numbers  
2 about compliance in that sense. And part of the concern  
3 seems to be the overnight use tool of running -- actually  
4 running the swamp cooler or not using it, for that matter.

5 DR. MOHAMMAD HEIDARINEJAD: Yeah. I mean,  
6 usually, in general, like during the nighttime it's  
7 cooler. So they are not running the coolers that much  
8 that's needed for the study here. So maybe like change of  
9 the study design. Is it like better to do it maybe during  
10 the day or something, rather than like morning and  
11 nighttime?

12 STEPHANIE JARMUL: Well, I guess the problem is  
13 if they were at work during the day though, then it  
14 wouldn't be capturing those exposures anyways. Can you  
15 talk a little bit more about -- Mohammad, about the plug  
16 load loggers --

17 DR. MOHAMMAD HEIDARINEJAD: Sure.

18 STEPHANIE JARMUL: -- and how they work to  
19 determine --

20 DR. MOHAMMAD HEIDARINEJAD: Yeah. Like if the --  
21 like for all the devices like portable air cleaners and  
22 swamp coolers as much as possible, so we had plug load  
23 loggers. So we -- meaning that we know when they are  
24 running it and how are they running it? Are they running  
25 it at low speed, medium speed, or high speed? So we're



1 able to capture like their usage and understand --  
2 especially for portable air cleaners and the swamp  
3 coolers. If you are running it at a low speed for  
4 portable air cleaners, so you're not getting enough clean  
5 air delivery rate, CADR.

6 So ideally you want to make sure you run it at  
7 high speed to get that portable air cleaner like removal  
8 efficiency needed. The same thing with like the swamp  
9 coolers. If you're running it at a higher speed, meaning  
10 they're pulling more air coming in, even if you have the  
11 filters on, they might not be effective at some point.

12 But I would say in terms of like compliance and  
13 running it during the nighttime, we were able to identify  
14 a method to know when they're running their swamp cooler  
15 based on the outdoor temperature. We call it like  
16 predicted to be on and also like measured on. And during  
17 the nighttime usually it's cooler, so they are not running  
18 those coolers, as much as you could see in terms of the  
19 filtration efficiency there.

20 DR. MARTHA SANDY: Martha Sandy, OEHHA. So I  
21 wasn't part of the study design team, but a couple years  
22 previous to when this study -- when they were in the  
23 field, we had multiple summers with lots of wildfire smoke  
24 events, when it was hot, you know, the dog days of August,  
25 for instance, and you would predict they would have had

1 their swamp coolers on at night. I'm just -- and someone  
2 may want to add more.

3 DR. MOHAMMAD HEIDARINEJAD: Yeah, that's -- I  
4 mean, that's really in terms of the why part. I think the  
5 maximum we got in that September was about maximum, maybe  
6 35 microgram per cubic meter compared to what you see  
7 during the wildfire time, usually that get to 100, 150.  
8 So we didn't have that magnitude at that time.

9 The other one is like, of course, the extreme  
10 heat become a factor there. When it's like significantly  
11 warmer, you run the cool air more than before.

12 DR. NERISSA WU: So this is Nerissa. I had a  
13 question. Did you get any feedback from participants  
14 about the use of the swamp coolers, in terms of noise or  
15 the expense of running it? As an intervention, is it  
16 something that be would acceptable to the families to have  
17 them on?

18 DR. MOHAMMAD HEIDARINEJAD: Sure. I mean, we had  
19 a survey. I think, Julie, you looked at the survey, but I  
20 can answer a few things. Like looking at the pilot year,  
21 for example, we had DIY air cleaners, like these  
22 Corsi-Rosenthal, you know, air cleaners there. Like  
23 usually they didn't like it because it was moving a lot of  
24 air in the room, so they were like putting it in the  
25 closet or somewhere else, so that's why we decided in the

1 full intervention to go with smaller units, that they are  
2 more effective, but smaller, and they don't run that  
3 amount of air flow in the space.

4 In terms of the swamp coolers, I think one of the  
5 complaints they had was if you are getting these swamp  
6 coolers with different like very, like, you know, random  
7 shapes, like the narrow ones, so you end up maybe using  
8 like four or six maybe filters rather than three or four  
9 that is like recommended. So that's why it becomes a  
10 little bit bulky and they didn't like that one.

11 But I think it's an iterative process. Over time  
12 you like run different filters install them, get the  
13 feedback, and overtime you can polish these DIY solutions  
14 with a combination of filters, and, you know, like, you  
15 know, seeing like sheet filters that could be appended to  
16 those like narrow version of the swamp coolers.

17 Julie, I don't know if you want to add anything  
18 about the survey. We did a survey of the 50 homes,  
19 correct?

20 JULIE VON BEHREN: Hi. Julie Von Behren, UCSF.

21 We did ask some satisfaction related surveys for  
22 the ECUs. And one of the things that I just wanted to add  
23 to what you already said was that cost was a definite  
24 issue. We asked about a price point. Would they be  
25 comfortable spending, because it is a DIY. And I think it

1 was pretty low, like \$20 or less, is what they indicated.

2 DR. MOHAMMAD HEIDARINEJAD: That's true, yeah. I  
3 think if I recall correctly, it was 20. Thank you, Julie.  
4 And our solution from the beginning, we were aiming about  
5 maybe \$100. But we ended up going a little bit higher  
6 than that. Also like, Ileana, if you have more from the  
7 field, that would be good.

8 ILEANA NAVARRO: You know, we -- I don't think we  
9 ever received any complaints about noise or the air  
10 cleaners being too loud, nor the air filters on the swamp  
11 coolers. I think what Mohammad said about it being bulky  
12 and just the size of it was the only issue, but yeah, no  
13 complaints about noise.

14 ACTING CHAIR PADULA: Go ahead, Carl.

15 Sorry, you need a mic.

16 PANEL MEMBER CRANOR: Thank you. Carl Cranor.  
17 UC Riverside. I want to ask a big question. You've  
18 studied a group of substances that are worth studying. If  
19 you took the universe of airborne toxicants, what have you  
20 left out? Do you know? Have you thought about them?

21 (Laughter).

22 STEPHANIE JARMUL: I mean, we do think about them  
23 ahead of all of our studies and sort of what's most  
24 relevant to measure. We always do research ahead of time  
25 to figure out what we might expect to see based on the

1 exposure sources that we're interested in, particularly  
2 air pollution. And again though, it also depends on what  
3 we're able to measure based on our designated list and  
4 also what our labs can measure. So I think that is a big  
5 limitation is sort of what methods have been developed or  
6 not been developed. But I'm sure there are things that we  
7 are missing and we continue to evolve and add more  
8 chemicals as we can. But if you have any ideas --

9 PANEL MEMBER CRANOR: Let me ask -- let me ask  
10 you about one of them.

11 STEPHANIE JARMUL: Okay.

12 PANEL MEMBER CRANOR: Air particulates are really  
13 nasty. I mean, you haven't done those I suppose or these  
14 are components of air particulates, but should the air  
15 particulates be studied in a similar way?

16 STEPHANIE JARMUL: Are you talking about  
17 particulate matter, in particular, like a biomarker for  
18 particulate matter?

19 PANEL MEMBER CRANOR: Sure.

20 (Laughter).

21 STEPHANIE JARMUL: You know, I'm pretty sure -- I  
22 don't know if Jeff Wagner is on. I think he's done some  
23 work sort of looking more closely at like breaking down  
24 the particulate matter in air and getting more ideas of  
25 like what it's actually made up of. Jeff, are you on and

1 want to talk a little bit more about that?

2 DR. JEFF WAGNER: Yeah.

3 (Laughter).

4 DR. JEFF WAGNER: So -- I'll go on camera. Yeah.

5 We are -- our lab did -- in addition to the continuous  
6 monitoring that Mohammad was talking about today, we did  
7 electron microscopy of the particulate matter. And so we  
8 were able to get the different size fractions, the  
9 different chemical components and some source information  
10 about the different particle types.

11 So we looked at fine particles, coarse particles,  
12 metals in the particles, but I have a feeling you might  
13 also be asking about what Stephanie mentioned, which is  
14 some kind of biomarker of the particles themselves. And  
15 that's an interesting question. I'm only familiar with  
16 that type of work for microplastics personally, as far as  
17 particles that don't dissolve and persist in particulate  
18 form in various fluids and tissues. So I don't know,  
19 that's an interesting question. Also asbestos. Other  
20 types of persistent particles that don't break down and  
21 would be detectable in tissues or fluids. I think that's  
22 an interesting question.

23 REBECCA BELLOSO: Hi. This is Rebecca Belloso  
24 from OEHHA. We do have three comments from attendees  
25 online. So I'll start reading the first one.

1           It's from an anonymous attendee. "I remember  
2 hearing about widespread outdoor grilling in the Central  
3 Valley and that it contributes to poor air quality. Would  
4 this contribute to naphthalene? Though it seems odd that  
5 other PAHs didn't increase given grilled food contains  
6 high levels."

7           STEPHANIE JARMUL: I think they stated it.

8           (Laughter).

9           STEPHANIE JARMUL: They answered my question.  
10 But also, again, we did find naphthalene in the air,  
11 although not at particularly higher levels than we've seen  
12 in other studies. And we did not see any associations  
13 with naphthalene in air and the naphthalene metabolites.  
14 But we only had eight outdoor air monitors. So we didn't  
15 have as specific of data for the outdoor air as we did for  
16 the indoor for the chemicals, including naphthalene.

17           REBECCA BELLOSO: Thank you. The second question  
18 is also from an anonymous attendee. "I believe  
19 nap-containing mothballs are not allowed to be sold in  
20 California."

21           STEPHANIE JARMUL: Great point. That is also  
22 true. Although, you still could technically buy them. I  
23 think we've even found them in some stores and you can buy  
24 them online, but you are not supposed to.

25           (Laughter).

1 REBECCA BELLOSO: And the third question is also  
2 from one anonymous attendee. "How does your LOD compare  
3 to NHANES for naphthalene?"

4 And I believe Dan Sultana may have an answer to  
5 that.

6 DAN SULTANA: Yeah. So our -- it was a -- the --  
7 it was about half of what the NHANES LOD was, but both  
8 NHANES and FRESSCA have hundred percent detection rates.  
9 So we don't think it's as elevated -- LOD difference isn't  
10 explaining the higher levels we're seeing.

11 ACTING CHAIR PADULA: Any other questions online?

12 Okay, José.

13 PANEL MEMBER SUÁREZ: Since we're talking about  
14 naphthalene, I'm looking at here the -- your -- the  
15 results that you have for the overnight difference.

16 STEPHANIE JARMUL: Um-hmm.

17 PANEL MEMBER SUÁREZ: So this is -- so these  
18 differences are actually not the night and the morning.  
19 Kind of. Tell me a little bit about that, because it  
20 is -- you collected the urine in the morning and then in  
21 the evening, right?

22 STEPHANIE JARMUL: So the first sample was  
23 collected, let's say, on a Tuesday after work. We  
24 instructed them immediately upon coming home from work  
25 take a urine sample. And then 12 hours later when they



1 woke up to take the first morning sample. Yeah, so it  
2 was --

3 PANEL MEMBER SUÁREZ: So it was evening and then  
4 morning.

5 STEPHANIE JARMUL: Exactly, yes.

6 PANEL MEMBER SUÁREZ: Okay. So then it makes  
7 sense. So, I mean, the interesting thing here is that the  
8 concentrations do go up overnight --

9 STEPHANIE JARMUL: I know.

10 PANEL MEMBER SUÁREZ: -- which really is pointing  
11 not at a nutritional source necessarily, unless it takes a  
12 little bit of time for it to -- if they ate something at 5  
13 p.m., some meat that had it, maybe gets absorbed and you  
14 see it in the morning. The other one would be maybe  
15 there's something in the indoor environment that's leading  
16 to that.

17 STEPHANIE JARMUL: And it's -- you know, based on  
18 this recent study that came out on hairdressers, and just  
19 some more evidence that we had that, you know, it could be  
20 used in dyes and fragrances. I'm wondering if it's, you  
21 know, in some sort of personal care products and it's  
22 maybe being hidden under the label of fragrance. We don't  
23 know, but that's one of our pet theories.

24 PANEL MEMBER SUÁREZ: Under fragrance, you would  
25 think of naphthalene, really?

1           STEPHANIE JARMUL: Yeah.

2           DR. MOHAMMAD HEIDARINEJAD: These measurements  
3 are conducted in October?

4           STEPHANIE JARMUL: Correct. Yeah. This one is  
5 specifically October, yeah.

6           DR. MOHAMMAD HEIDARINEJAD: So that's why maybe  
7 during the night, they don't need to run the swamp cooler.

8           STEPHANIE JARMUL: Exactly. Yeah.

9           ACTING CHAIR PADULA: And that was the time that  
10 the swamp coolers were put on, even though there was no  
11 wildfire too, so there was kind of a less of (inaudible).

12           STEPHANIE JARMUL: Yeah. We had a hurricane  
13 during that season, where we actually -- I can't remember  
14 if you were there -- Mohammad was there, but a team had to  
15 go and remove -- at least CCEJN was very involved --  
16 remove the filters during the hurricane and then put them  
17 back on. So it was a very strange year that that  
18 happened --

19           (Laughter).

20           STEPHANIE JARMUL: -- that we weren't really  
21 prepared for.

22           PANEL MEMBER SUÁREZ: No. I do want to  
23 congratulate you though for the work -- the whole -- I  
24 mean, you can tell there was so much thought process going  
25 in there. It is very challenging to do an intervention

1 like this, especially with the cost, the filtration, the  
2 monitoring, the biomonitoring, so many different  
3 components. In that sense, I think it was a very  
4 successful intervention, and not only from the indoor part  
5 of things. Of course, it didn't turn out with all the  
6 VOCs and things like those, but there are reasons to  
7 believe that, given the right conditions, it may actually  
8 be far more beneficial than what we're observing, right?  
9 There were no major events of fire that happened for you  
10 to really look at the differences.

11 So I think it's very encouraging that this is,  
12 you know, very easily implementable. And it seems to be  
13 moderately well received intervention by the different  
14 communities.

15 STEPHANIE JARMUL: Thank you. And just a big --  
16 I want to make sure I give a big shout-out to Gina Solomon  
17 and Nayamin Martinez, who were the initial PIs of the  
18 FRESSCA and FRESSCA-Mujeres studies and sort of brought  
19 this larger great team together.

20 ACTING CHAIR PADULA: I just have one follow-up  
21 question to this conversation. I was wondering if  
22 we've -- if -- I guess some of this makes me want to look  
23 into the work of Ami Zota, who's done a lot on hair  
24 products and chemicals. And I was wondering if that's  
25 come up?

1           STEPHANIE JARMUL: Yes. We are looking into it.  
2 We are aware of it.

3           ACTING CHAIR PADULA: Okay.

4           STEPHANIE JARMUL: Yes.

5           ACTING CHAIR PADULA: Great. And then I was just  
6 also wondering about the energy costs, whether that was of  
7 concern?

8           DR. MOHAMMAD HEIDARINEJAD: Not a concern,  
9 because, in general, swamp coolers, like the cost of  
10 operation, it's about like maybe one quarter of if you're  
11 running like split systems.

12          ACTING CHAIR PADULA: Okay.

13          DR. MOHAMMAD HEIDARINEJAD: So like that's not a  
14 concern, but technically if you're adding a filter to the  
15 swamp coolers, you're increasing a little bit the power  
16 consumption, but not as much as like that could be a  
17 concern.

18          STEPHANIE JARMUL: Jenny has a question.

19          ACTING CHAIR PADULA: Great. Jenny, you want to  
20 go ahead.

21          PANEL MEMBER QUINTANA: Sure. I think there's  
22 time for just a quick question. Just -- I was just  
23 wondering about housing type and if it was -- differed  
24 from other housing? And I guess I was just thinking of  
25 that whole FEMA trailers and formaldehyde, know, thing

1 with the Hurricane Katrina. So it just made me think  
2 about housing type and if they're more likely to be  
3 manufactured housing or something like that.

4 Thank you.

5 DR. MOHAMMAD HEIDARINEJAD: They're usually like  
6 manufactured housing, smaller ones in terms of their like  
7 square footage, but they are usually smaller than the  
8 typical we see in the U.S.

9 STEPHANIE JARMUL: And I think for the  
10 biomonitoring samples, we did look into any potential  
11 differences based on housing type and we did not see any.

12 PANEL MEMBER QUINTANA: Thank you.

13 DR. MOHAMMAD HEIDARINEJAD: And just going back  
14 to the energy cost questions, like for different projects  
15 we are paying participants for running the portable air  
16 cleaner all the time, but that doesn't help to make sure  
17 they're running it.

18 (Laughter).

19 ACTING CHAIR PADULA: All right. If that's it  
20 for questions. I think we'll wrap-up and thank you to the  
21 FRESSCA team for a great presentation.

22 (Applause).

23 ACTING CHAIR PADULA: So in our next agenda item,  
24 we will be hearing from Stephanie again.

25 (Laughter).

1           ACTING CHAIR PADULA: Sorry, you can't sit down  
2 yet. She'll provide a brief overview of the planning for  
3 SGP meetings in 2026.

4           (Slide presentation).

5           STEPHANIE JARMUL: Thank you. Almost forgot  
6 about this one.

7           (Laughter).

8           STEPHANIE JARMUL: So as Amy mentioned, I'm just  
9 going to briefly discuss our plans for next year's SGP  
10 meetings.

11                           [SLIDE CHANGE]

12           STEPHANIE JARMUL: So we worked with the Panel -  
13 always very difficult, since everyone one is so busy - to  
14 select the following dates for our meetings in 2026. So  
15 we have a meeting on Wednesday, March 4th from 1 to 4  
16 p.m., and then on Monday, August 3rd from 10 a.m. to 4  
17 p.m., and Monday, November 16th from 1 p.m. to 4 p.m.  
18 We're still going to be making determinations on each  
19 meeting's location. So we'll let everyone know closer to  
20 the meeting date and we'll update on our website, but we  
21 will still be having the hybrid format throughout 2026.

22           So we will also still have our standing agenda,  
23 which includes a general Program update, and then more  
24 detailed project updates, such as updates on our  
25 surveillance studies and community studies. As always,

1 we'll also have time for discussion and input from the  
2 Panel and audience. These are some other potential topics  
3 of interest that we've put forward that we could consider  
4 exploring.

5 [SLIDE CHANGE]

6 STEPHANIE JARMUL: And these include either  
7 internal or guest speaker presentations on the use of  
8 artificial intelligence in class-based semi-targeted  
9 screening. It seems we can't escape AI, even if we try.  
10 Exposure to microplastics, updates from international  
11 biomonitoring programs. I think it would be really  
12 interesting to hear what they're researching and some of  
13 their results, and then, of course, impacts of climate  
14 change, which has been on our list for a while, such as  
15 wildfires, droughts, et cetera, and their impacts on  
16 chemical exposures.

17 So now, we welcome any input from the Panel and  
18 audience on these suggestions and additional topics that  
19 we might consider. So I'll stop there and see if anyone  
20 would like to add anything or have any questions.

21 It sounds like we have something online.

22 REBECCA BELLOSO: Yes. We have Feng available.  
23 Let me unmute you.

24 STEPHANIE JARMUL: Feng, are you speaking?

25 REBECCA BELLOSO: I'm asking her to unmute.

1 Well, maybe we'll come back.

2 ACTING CHAIR PADULA: Maybe we'll take Tom's  
3 question first.

4 PANEL MEMBER MCKONE: Okay. I don't have a  
5 question, I guess. Well, a comment. So the use of  
6 artificial intelligence is probably a good idea. I mean,  
7 I think stuff is really emerging and to see how it fits.  
8 I was looking at the climate change issue. And, I mean, I  
9 know we're already doing -- that you're already doing  
10 studies about how climate change affects exposures to PM  
11 and a whole range of pollutants. I was just wondering if  
12 there's a way to begin to integrate -- I mean, not to call  
13 it a biomarker of climate change stress, but if there's a  
14 way to begin to organize, you know, the multiple stressors  
15 that arise from a change in climate into some way of  
16 expressing through stress biomarkers or exposure  
17 biomarkers how things are changing in the population, so,  
18 you know, to kind of quote say a climate change biomarker.  
19 But it might be possible to do something like that,  
20 define, you know, an array of things you could see in  
21 blood that would in -- would show the rising change in  
22 those markers of stress and exposure that we could  
23 associate with climate change. It's kind of a wild  
24 thought, but I mean, it would be different than just  
25 individual studies that say wildfires or heat stress or



1 one thing at a time, but more of an aggregated approach.

2 STEPHANIE JARMUL: Yeah, that's a great idea.

3 And it would be interesting to look at the biomarkers of  
4 stress. And the FRESSCA study did collect telomere length  
5 in saliva, which I think is also really interesting. And  
6 I don't know if that would be potentially something to  
7 look at too, maybe not by -- I don't if our Program could  
8 do that, but for others.

9 PANEL MEMBER SUÁREZ: I have a comment here for  
10 Oliver, actually, or questions --

11 (Laughter).

12 PANEL MEMBER SUÁREZ: -- or more so. Are you  
13 using AI when you're running untargeted analyses and  
14 things like that?

15 PANEL MEMBER FIEHN: Yeah. So in principle, AI  
16 is a multivariate analysis if you like. So if you have  
17 many, many parameters and you have some output, you can  
18 always use AI. So it's a little bit like a progression  
19 from machine learning that we had in the past, right? So  
20 it's not -- in the sense, AI was already invented in the  
21 1960s, but they didn't have the computers for it, right?  
22 Now, we can get really complicated complex, you know,  
23 questions answered this way, as you all know. Now, for  
24 our non-targeted analysis, my own lab, we do it for  
25 retention time prediction, right?

1           So when you have -- let's assume you have a  
2 thousand or two thousand compounds that you see and you  
3 want to identify that. The question is how often are you  
4 wrong, right, and how can you be not so wrong when you say  
5 I found 2-naphthol or whatever, right, instead of like  
6 somewhere else that -- some other -- some other isomer,  
7 and that's why we use it, but we also use it for  
8 multi-omic integration.

9           So when you have, for example, the prediction of  
10 microbiomes that you want to see, what can -- what can  
11 they together produce? So any of these AI methods is  
12 really looking at large data sets and complex data sets.  
13 So the question is that I would have here is do we have  
14 those data sets and do we have some kind of outcomes that  
15 we could, you know, basically regress on? It's like a --  
16 like a regression, just like a little more complicated  
17 than a regression, but yeah, right?

18           So that is -- that is how we use it these days.  
19 Can there be other uses? Yeah. I -- when I looked at  
20 this topic, I thought like do we have enough experts or  
21 literature to kind of fill it, right? That was a little  
22 bit my question.

23           STEPHANIE JARMUL: Sounds like you might be one  
24 of them?

25           (Laughter).

1 PANEL MEMBER FIEHN: Yeah, yeah, yeah, but, you  
2 know, okay. But in terms of environmental exposure, you  
3 know, that's the -- that's the -- that's the thing, and  
4 what exactly would we use it for, right? You know, when  
5 you look at all the presentations we've had here, there  
6 are usually unique barriers. You have a compound, you  
7 have a regression in time, or -- you know, and then you  
8 have -- or you have box plots, you know, before, after,  
9 right? So this is like classic statistics, right, which  
10 is fine, you know.

11 And also to Tom's question, right, can we get a  
12 multi-stress composite? That's an AI question actually,  
13 right? So but then the next question is do we have the  
14 data for it, right? And also some kind of where do we get  
15 the data? Is it like coherent? It's like -- it's not  
16 that easy. People -- it's easy to say AI. It's hard to  
17 get the data for it. That's what I'm thinking.

18 STEPHANIE JARMUL: Great question. Great answer.

19 (Laughter).

20 STEPHANIE JARMUL: Did Feng ever figure out how  
21 to unmute? Okay. Okay.

22 Well, we welcome input any time to our email or  
23 you can contact me directly.

24 Oh, Oliver does have something.

25 PANEL MEMBER FIEHN: So, you know, I had wondered

1 a little bit what our target lists to our chemical lists.  
2 Should we also want an update on that. And, you know,  
3 when we put things on the designated list, you know, have  
4 we considered measuring some of them, or are there new  
5 chemicals that we should discuss? I have the feeling we  
6 haven't done it for a while.

7           STEPHANIE JARMUL: Yeah. The last time was  
8 expanding the PFAS list a couple of years ago, but yeah.  
9 And certainly if there is any chemicals that people have  
10 in mind that are -- they have interest of adding to the  
11 list, if it's not already on, please let us know.

12           ACTING CHAIR PADULA: Maybe just before I wrap  
13 up, I'll just have maybe one other comment in that -- I  
14 mean, personally I'm really interested in the combination  
15 between that first AI or use of semi or even non-targeted  
16 screening, potentially in ones that have already been --  
17 you know, biospecimens that are available or analyses that  
18 have already been run, and then rerun them with wildfire  
19 or even other climate change factors in mind. So kind of  
20 go back and reanalyze the data with kind of new exposure  
21 metrics, maybe separating them out by maybe a high climate  
22 stress versus not, and then see if there are any  
23 differences in some of these non-targeted things, based on  
24 that, and -- yeah.

25           STEPHANIE JARMUL: Thanks. That would be very

1 interesting to see.

2 ACTING CHAIR PADULA: At least, if it's already  
3 done, then it's maybe not so costly too.

4 (Laughter).

5 ACTING CHAIR PADULA: Great. I think then that  
6 puts us into the open public comment period. Thank you,  
7 Stephanie, for our Program plans for next year.

8 So we have about 10 minutes allotted for this  
9 period. So webinar attendees can submit written comments  
10 and questions via the Q&A function of the Zoom webinar or  
11 by email to [biomonitoring@oehha.ca.gov](mailto:biomonitoring@oehha.ca.gov), and we will read  
12 them out loud. And if you wish to speak, please alert us  
13 with using the raise hand feature in Zoom and Rebecca will  
14 call on you to share your comments live. And then if  
15 you're attending in person or wish -- and wish to comment,  
16 please come to the front or raise your hand and we'll call  
17 on you and bring you a microphone. And for the benefit of  
18 the transcriber, we encourage you to identify yourself  
19 before providing comment, and -- however, there's no  
20 obligation, if you would like to comment anonymously.

21 This is the quiet before the storm.

22 (Laughter).

23 ACTING CHAIR PADULA: And are there any online?

24 REBECCA BELLOSO: No, we haven't received any  
25 comments online.

1           ACTING CHAIR PADULA: So there will be a  
2 transcript of this meeting posted on the Biomonitoring  
3 California website when available. And as mentioned  
4 earlier, the next SGP meeting will take place on March  
5 4th, 2026 from 1 to 4 in Oakland. And information  
6 regarding options for attending the meeting will be made  
7 available closer to the March meeting date.

8           But thank you to the Panel and audience and the  
9 meeting is adjourned.

10           (Thereupon the California Environmental  
11 Contaminant Biomonitoring Program, Scientific  
12 Guidance Panel meeting adjourned at 3:52 p.m.)  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

CERTIFICATE OF REPORTER

I, JAMES F. PETERS, a Certified Shorthand Reporter of the State of California, do hereby certify:

That I am a disinterested person herein; that the foregoing California Environmental Contaminant Biomonitoring Program Scientific Guidance Panel meeting was reported in shorthand by me, James F. Peters, a Certified Shorthand Reporter of the State of California, and thereafter transcribed under my direction, by computer-assisted transcription.

I further certify that I am not of counsel or attorney for any of the parties to said meeting nor in any way interested in the outcome of said meeting.

IN WITNESS WHEREOF, I have hereunto set my hand this 4th day of December, 2025.



JAMES F. PETERS, CSR  
Certified Shorthand Reporter  
License No. 10063